

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Incidence of anorexia nervosa in young people in the United Kingdom and the Republic of Ireland: A national surveillance study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-027339
Article Type:	Research
Date Submitted by the Author:	17-Oct-2018
Complete List of Authors:	Petkova, Hristina; King's College London, Health Service and Population Research Department Simic, Mima; South London and Maudsley NHS Foundation Trust Nicholls, Dasha; Imperial College London Ford, Tamsin; University of Exeter, Medical School Prina, A.Matthew; King's College London, Stuart, Ruth; King's College London, Health Service and Population Research Department Livingstone, Nuala; Queen's University Belfast Kelly, Grace; Queen's University Belfast Macdonald, Geraldine; University of Bristol Eisler, Ivan; South London and Maudsley NHS Foundation Trust Gowers, Simon; University of Liverpool Barrett, Barbara; King's College London Byford, Sarah; King's College London, Health Service and Population Research Department
Keywords:	Eating disorders < PSYCHIATRY, Child & adolescent psychiatry < PSYCHIATRY, EPIDEMIOLOGY

SCHOLARONE™
Manuscripts

1
2
3 **Incidence of anorexia nervosa in young people in the United Kingdom and the Republic of**
4 **Ireland: A national surveillance study**

5
6 Hristina Petkova, Institute of Psychiatry, Psychology & Neuroscience at King's College London
7 (Research Fellow).
8

9
10 Mima Simic, South London and Maudsley NHS Foundation Trust (Consultant Child and
11 Adolescent Psychiatrist).
12

13 Dasha Nicholls, Imperial College London (Reader in Child and Adolescent Psychiatry).
14

15 Tamsin Ford, University of Exeter Medical School (Professor of Child and Adolescent
16 Psychiatry).
17

18 A. Matthew Prina, Institute of Psychiatry, Psychology & Neuroscience at King's College
19 London (Senior Lecturer in Epidemiology).
20

21 Ruth Stuart, Institute of Psychiatry, Psychology & Neuroscience at King's College London
22 (Research Assistant).
23

24 Nuala Livingstone, Queen's University Belfast (Research Fellow).
25

26 Grace Kelly, Queen's University Belfast (Research Fellow).
27

28 Geraldine Macdonald, University of Bristol (Professor of Social Work).
29

30 Ivan Eisler, South London and Maudsley NHS Foundation Trust (Professor of Family
31 Psychology and Family Therapy).
32

33 Simon Gowers, University of Liverpool (Professor of Adolescent Psychiatry).
34

35 Barbara Barrett, Institute of Psychiatry, Psychology & Neuroscience at King's College London
36 (Senior Lecturer in Health Economics).
37

38 Sarah Byford, Institute of Psychiatry, Psychology & Neuroscience at King's College London
39 (Professor of Health Economics).
40
41

42
43
44 Corresponding author: Sarah Byford, Institute of Psychiatry, Psychology & Neuroscience at
45 King's College London, P024 David Goldberg Centre, De Crespigny Park, London SE5 8AF,
46 UK, s.byford@kcl.ac.uk, 02078480043
47
48
49
50
51
52
53
54
55
56
57

Abstract

Objectives: This study aimed to estimate the incidence of DSM5 anorexia nervosa in young people in contact with child and adolescent mental health services in the UK and Republic of Ireland.

Design: Observational, surveillance study using the Child and Adolescent Psychiatry Surveillance System, involving monthly reporting by child and adolescent psychiatrists between 1st February 2015 and 30th September 2015.

Setting: UK and Republic of Ireland

Participants: Clinician-reported data on young people aged 8 to 17 in contact with child and adolescent mental health services for a first episode of anorexia nervosa.

Main outcome measures: Annual incidence rates estimated as confirmed new cases per 100,000 population at risk.

Results: 305 incident cases of anorexia nervosa were reported over the 8-month surveillance period and assessed as eligible for inclusion. The majority were young women (91%), from England (70%), and of white ethnicity (92%). Mean age was 14.6 years (± 1.66) and mean percentage of median expected BMI for age and sex was 83.23% ($\pm 10.99\%$). The overall incidence rate, adjusted for missing data, was estimated to be 13.68 per 100,000 population (95% CI 12.88 to 14.52), with rates of 25.66 for young women (95% CI 24.09 to 27.30) and 2.28 for young men (95% CI 1.84 to 2.79). Incidence increased steadily with age, peaking at 15 for young women (57.77, 95% CI 50.41 to 65.90) and 16 for young men (5.14, 95% CI 3.20 to 7.83). Comparison with earlier estimates suggests incidence rates for children aged 13 and under have increased over the last ten years.

Conclusions: These results provide up-to-date estimates of the incidence of anorexia nervosa in young people. Service providers and commissioners should consider evidence to suggest an increase in incidence in younger children.

Study registration: International Standard Randomised Controlled Trial Number Register [ISRCTN12676087].

Strengths and limitations of this study

- Estimates of the incidence of anorexia nervosa in the UK and Republic of Ireland are limited and at least ten years old.
- This study provides up-to-date estimates of the incidence of DSM5 anorexia nervosa in young people aged 8 to 17 years in contact with child and adolescent mental health services across the UK and Republic of Ireland.
- The surveillance design of this observational study ensured a large, nationally representative sample.
- Missing data due to non-response was a limitation and required adjustments to observed data to account for the impact of this missing data.

Introduction

Anorexia nervosa is a serious and enduring eating disorder with high morbidity and the highest mortality among psychiatric disorders.¹ Young women are particularly susceptible, with annual UK estimates of 37 new diagnoses of anorexia nervosa per 100,000 for girls aged 10 to 19 years, compared to 3 per 100,000 for boys of the same age.² Prevalence estimates in young people range from 0.3% to 0.6%.³⁻⁴

Accurate epidemiological estimates of the number of new anorexia nervosa cases per year and their sex and age profile are needed for causal investigations and service planning.² However, available estimates in the UK are at least ten years old.^{2,5-7} In addition, most estimates are derived from community-based primary care records,^{2,5} which fail to accurately record all new cases.^{8,9} Undetected anorexia nervosa cases may present to accident and emergency and require immediate paediatric or psychiatric input, including inpatient admission. Some young people may therefore bypass primary care and, consistent with UK guidelines,¹⁰ are likely to be assessed and diagnosed by a child and adolescent psychiatrist in a secondary care setting, making secondary care records a more reliable source of data on anorexia nervosa incidence than primary care registers.

Existing incidence data from secondary care settings in the UK are limited. One study, focusing only on adolescents aged 13 to 18, was limited to Greater London and reported presentation rates to child and adolescent mental health services (CAMHS), rather than incidence estimates.⁶ A second study, which used a national surveillance design, focused only on children under 13.⁷ The current study aimed to estimate the incidence of anorexia nervosa in secondary care services for young people between the ages of 8 and 17 years in the UK and the Republic of Ireland. This work formed part of a study exploring the cost-effectiveness of models of care for young people with eating disorders (the CostED study).¹¹

Methods

Design

An observational, surveillance study was undertaken using the Child and Adolescent Psychiatry Surveillance System (CAPSS). CAPSS is a system designed to ascertain cases of rare childhood

1
2
3 mental health conditions in the UK and Republic of Ireland through monthly reporting by
4 clinicians and relies on non-consent to maximise the accuracy of epidemiological estimates. The
5 CAPSS system has been operating since 2009¹² and is based on the well-established British
6 Paediatric Surveillance Unit (BPSU) system.¹³
7
8
9

10 11 12 ***Ethics approvals***

13 The study was approved by the CAPSS Executive Committee, King's College London Research
14 Ethics Committee [PNM/13/14-105], and the Health Research Authority Confidentiality
15 Advisory Group [CAG 4-03(PR1)/2014] under Section 251 of the NHS Act 2006, which enables
16 disclosure of confidential patient information for purposes where it is not possible to use
17 anonymised information and where seeking consent is not practical.
18
19
20
21
22

23 24 ***Patient and public involvement***

25 The CostED study included a patient and a parent representative on the study steering committee
26 who contributed to the design, conduct and management of the study, including the incidence
27 component. A lay summary of the CostED study results will be produced, in collaboration with
28 Beat, the national eating disorder charity, for dissemination via the Beat website.
29
30
31
32
33

34 35 ***Inclusion and exclusion criteria***

36 The study included young people between 8 and 17 years of age, in contact with CAMHS for a
37 first episode of anorexia nervosa according to DSM5 diagnostic criteria.¹⁴ New cases were
38 notified for a period of eight months from 1st February to 30th September 2015. Cases whose
39 clinician-reported data were insufficient to assess eligibility were excluded, as were duplicate
40 cases notified more than once by the same or different clinicians.
41
42
43
44
45

46 47 ***Procedures***

48 At the time of the study, CAPSS used a report card, known as the yellow card, containing a list
49 of conditions being surveyed. Yellow cards, along with reporting instructions and protocols for
50 new studies, are sent monthly from the CAPSS office to a mailing list of all hospital, university
51 and community child and adolescent consultant psychiatrists across the United Kingdom and the
52 Republic of Ireland. Reporting clinicians are asked to check boxes against any of the reportable
53
54
55
56
57

1
2
3 conditions they have seen in the preceding month, or to check a "nil return" box and return the
4 card to CAPSS. A tear-off slip is provided for respondents to keep a record of the patients
5 reported. "Positive" returns are allocated a unique CAPSS ID number and notified to the
6 appropriate research investigator, who then contacts the reporting clinician directly to request
7 completion of a questionnaire using the CAPSS ID to enable the clinician to identify the relevant
8 patient.
9
10
11
12
13
14

15 For the CostED study, the yellow card contained a check box for anorexia nervosa and was sent
16 to clinicians along with a protocol card detailing the case notification definition for anorexia
17 nervosa. The case notification definition (see web extras) was based on DSM5 diagnostic criteria
18 for anorexia nervosa and was intended to aid clinicians in their decision to tick "yes" or "no" on
19 the yellow card. It was not intended to identify whether a case met study inclusion criteria, which
20 was determined by the research group after receipt of all necessary data.
21
22
23
24
25
26

27 *Data*

28 Questionnaires sent to clinicians reporting a positive case of anorexia nervosa, identified via the
29 unique CAPSS ID number, were completed from clinical records and clinicians requested to
30 provide data relating to the time the case was initially assessed and diagnosed. The questionnaire
31 covered clinical features to enable assessment of case eligibility, referral pathway information to
32 ensure assessment and diagnosis had not happened prior to the study surveillance period, and a
33 limited set of standard patient identifiers in line with CAPSS procedures and ethics requirements,
34 which were used to describe the sample and to identify duplicate notifications. In addition,
35 clinicians were asked to confirm whether the case was a first episode of anorexia nervosa that
36 had come to the attention of services.
37
38
39
40
41
42
43
44
45

46 The patient identifiers included NHS or Community Health Index (CHI) number (unique patient
47 identifiers used in the regions of interest), hospital number, first half of postcode or town of
48 residence for the Republic of Ireland, sex, date of birth and ethnicity (White, Mixed, Asian,
49 Black, Chinese, Other or Unknown). In Northern Ireland, identifiers were limited to age in years
50 and months and hospital identifier rather than hospital number, to reduce the risk of patient
51 identification given the small geographic area. All patient identifiable data from Northern Ireland
52
53
54
55
56
57

1
2
3 were retained by the local research team, de-duplicated, anonymised and subsequently sent to the
4 central research team in King's College London for analysis as per requirements set out by the
5 Northern Ireland Privacy Advisory Committee. All data storage was compliant with the EU
6 General Data Protection Regulations.
7
8
9

10
11 Clinical features included: weight and height to calculate body mass index (BMI) and percentage
12 of median expected BMI for age and sex interpreted around the 85% threshold;¹⁵ The Health of
13 the Nation Outcome Scales for Children and Adolescents (HoNOSCA¹⁶), a routine outcome
14 measure rating 13 clinical features on a five-point severity scale including behaviours,
15 impairments, symptoms, and social functioning of children and adolescents with mental health
16 problems; the clinician completed Children's Global Assessment Scale (CGAS¹⁷) used to rate
17 emotional and behavioural functioning of young people; and a range of symptoms relating to the
18 diagnosis of anorexia nervosa.
19
20
21
22
23
24
25
26

27 Unreturned or incomplete questionnaires were chased via email and telephone. Cases where any
28 symptom required for case definition was absent despite chasing, were assessed for eligibility by
29 a consultant child and adolescent psychiatrist (MS).
30
31
32
33

34 *Case eligibility*

35
36 Cases were assessed as eligible for the study if: (a) they were between 8 and 17 years of age; (b)
37 they had no previous episode of anorexia nervosa that had come to the attention of services; (c)
38 they received a clinical assessment in the reporting service during the study surveillance period;
39 (d) they had not been referred from another secondary health service (to ensure assessment and
40 diagnosis had not happened prior to study surveillance period); and (e) the following clinical
41 symptoms were present: "Restriction of energy intake relative to requirements" and "Persistent
42 behaviour that interferes with weight gain, despite low weight". This broad definition was
43 subsequently checked using a tighter DSM5 analytic definition including the following
44 symptoms:
45
46
47
48
49
50

- 51 1) "Restriction of energy intake relative to requirements" and
- 52 2) "Intense fear of gaining weight or of becoming fat" or "Persistent behaviour that
53 interferes with weight gain, despite low weight" and
54
55
56
57

- 1
2
3 3) “Perception that body shape/size is larger than it is” or “Preoccupation with body weight
4 and shape” or “Lack of recognition of the seriousness of the current low body weight”
5

6 Only one case which met the broad criteria failed to meet the tighter criteria, thus confirming the
7 validity of the broad criteria.
8
9

10 11 12 ***Removal of duplicates***

13 Duplicates were identified by comparing NHS/CHI numbers, hospital numbers/ hospital
14 identifiers and date of birth/age in years and months, as appropriate. The management of
15 duplicates depended upon the outcome for the original notification for which a duplicate was
16 identified. Four scenarios were considered: (1) duplicates where the original notification met
17 study inclusion criteria were excluded and the original retained; (2) duplicates where the original
18 notification had been excluded because the young person was under 8 years of age or did not
19 meet the clinical criteria were assessed as a new case to determine if the case now met eligibility
20 criteria; (3) duplicates where the original notification was excluded due to a previous episode of
21 anorexia nervosa, a diagnosis date prior to the study surveillance period or referral from another
22 secondary care service, were excluded; and (4) duplicates where the original notification
23 contained insufficient information to judge eligibility were checked to see if the duplicate
24 contained the missing information and, if available, the original notification was reassessed for
25 eligibility and the duplicate managed as per the scenarios above.
26
27
28
29
30
31
32
33
34
35
36
37

38 ***Data analysis***

39 Data analysis was performed using Stata IC v14.2 and Microsoft Excel 2010. Observed
40 incidence rates (denoted IR0), defined as the number of new cases during a specified period of
41 time in a population at risk for developing the disease, were calculated as follows: the number of
42 confirmed new cases of anorexia nervosa in the 8-month surveillance period converted to 12
43 months [(N cases over 8 months/8)*12], divided by the population at risk and multiplied by
44 100,000 to give the rate per 100,000 young people.
45
46
47
48
49
50

$$51 \text{ IR0} = (\text{confirmed new cases converted to 12 months})/\text{the population at risk} *100,000$$

52
53
54
55
56
57

1
2
3 The population at risk was calculated as the total number of children of each year of age and
4 each sex in the UK and Republic of Ireland minus the number of prevalent cases who, once
5 diagnosed, are no longer part of the “at risk” population. Population data for 2015 were obtained
6 from the Office for National Statistics for the UK¹⁸ and the Central Statistics Office for the
7 Republic of Ireland.¹⁹ To estimate the number of prevalent cases each year, incident cases in the
8 previous age band were used as a proxy. For example, incident cases aged eight were used as a
9 proxy for prevalent cases in the estimation of the ‘at risk’ population aged nine, and so on.
10
11
12
13
14
15

16
17 To consider incidence among unobserved missing cases, adjustments were needed for unreturned
18 CAPSS notification cards and questionnaires. For CAPSS notification cards, just over half of all
19 notification cards sent out were returned (50.16%). To account for incidence among the 49.84%
20 of unreturned cards, two assumptions were made, and an appropriate correction applied to IRO,
21 the observed incidence rate:
22
23
24
25
26

27 *Assumption 1:* To take into consideration the possibility that unreturned cards are more likely to
28 be ‘nil’ returns, it was assumed that half of unreturned cards (24.92%) were ‘negative’ and half
29 followed the same proportion of ‘negative’ and ‘positive’ as the returned cards. This assumption
30 translates into a correction coefficient of 1.50 derived from $(24.92+50.16)/50.16$.
31
32
33
34
35

36 *Assumption 2:* Making no assumptions of bias in the likelihood of unreturned cards being either
37 positive or negative returns, it was assumed that all unreturned cards followed the same
38 proportion of ‘negative’ and ‘positive’ as returned cards. This assumption translates into a
39 correction coefficient of 1.99 derived from $(49.84+50.16)/50.16$.
40
41
42
43
44

45 These assumptions provide a range of incidence rates, from a minimum (observed incidence rate)
46 to a maximum (assumption 2), within which the actual rate is likely to fall. We hypothesised that
47 assumption 1 provides the most realistic estimate since it assumes a bias in the response rates
48 with greater likelihood that unreturned cards are negative (‘nil’ returns) but does not assume *all*
49 unreturned cards are ‘nil’ returns, which is the implicit assumption within IRO.
50
51
52
53
54
55
56
57
58
59
60

1
2
3 For unreturned questionnaires, approximately two-thirds of the questionnaires that were sent to
4 clinicians reporting positive cases of anorexia nervosa were returned (63%), leaving one-third
5 (37%) unreturned. Since all these questionnaires relate to a 'positive' notification, we applied a
6 correction coefficient of 1.59 derived from $(37+63)/63$, which assumes that the incidence rate for
7 the unreturned questionnaires is the same as the incidence rate identified in the returned
8 questionnaires for each year of age.
9
10
11
12
13

14
15 We then combined the correction coefficients described above, to generate two adjusted
16 incidence rates:
17
18
19

20
21 *Adjusted incidence rate 1 (IR1)* = Confirmed new cases of anorexia nervosa converted to 12
22 months, multiplied by the correction for unreturned CAPSS notification cards under assumption
23 1, multiplied by the correction for unreturned questionnaires, then divided by the population at
24 risk and multiplied by 100,000.
25
26
27

28
29
$$IR1 = (\text{confirmed new cases converted to 12 months} * 1.50 * 1.59) / \text{the population at risk} * 100,000$$

30
31
32

33
34 *Adjusted Incidence rate 2 (IR2)* = Confirmed new cases of anorexia nervosa converted to 12-
35 months, multiplied by the correction for unreturned CAPSS notification cards under assumption
36 2, multiplied by the correction for unreturned questionnaires and then divided by the population
37 at risk and multiplied by 100,000.
38
39
40
41

42
43
$$IR2 = (\text{confirmed new cases converted to 12 months} * 1.99 * 1.59) / \text{the population at risk} * 100,000$$

44
45
46

47
48 For each incidence rate, IR0, IR1 and IR2, total, age-specific and sex-specific annual incidence
49 rates for anorexia nervosa for the year 2015 and 95% confidence intervals were calculated based
50 on the Poisson distribution²⁰ using the Stata command *ci means [N new anorexia nervosa cases*
51 *12m], Poisson [exposure(total population)]* for positive integers/whole incidence numbers (Stata
52
53
54
55
56
57

1
2
3 interprets any non-integer decimal point number between 0 and 1 as the fraction of events and
4 converts it to an integer number). Annual incidence rates were stratified by discrete age and sex.
5
6
7

8 **Results**

9 ***Case ascertainment***

10 Case ascertainment is outlined in Figure 1. Over the eight-month surveillance period, 6401
11 yellow cards were sent to reporting clinicians and 3211 were returned (50%). Of these, 997
12 positive cases of anorexia nervosa were reported and 2214 were nil returns. Of the positive cases,
13 48 (5%) were excluded due to clinicians stating that they did not wish to be included in the study
14 (due to retirement, shortage of reporting capacity etc.) or due to reporting errors. Questionnaires
15 were sent to the remaining 949, and a further 352 positive cases (37%) were excluded as they
16 failed to return the questionnaires, so no data were available to assess eligibility. Questionnaires
17 were completed and returned for 597 notified cases, of which 292 (49%) were ineligible for
18 reasons related to age, previous episode of anorexia nervosa, date of assessment outside the
19 study's surveillance period, referral from another secondary care service, insufficient information
20 to assess diagnosis or duplicate notifications, leaving 305 incident cases of anorexia nervosa as
21 the sample for analysis.
22
23
24
25
26
27
28
29
30
31
32
33

34 ***Demographics and clinical features***

35 Of the 305 young people identified as having DSM5 anorexia nervosa, the majority were girls
36 (91%), from England (70%) and of white ethnicity (92%) (see Table 1). The mean age was 14.6
37 years (± 1.66). Clinical variables suggest these young people were significantly impaired. Mean
38 BMI was 16.50 kg/m² (± 2.25), where values of 16.00 to 16.99 suggesting moderate severity of
39 anorexia nervosa. Mean percentage of median expected BMI for age and sex (the deviation from
40 expected body weight) was 83.23% ($\pm 10.99\%$), falling within the range required for a diagnosis
41 of anorexia nervosa (<85%). Mean CGAS score was 44.61 (± 14.08), which falls within the range
42 for 'obvious problems' (41–50) on a scale from 1 to 100 (1 being the worst and 100 the best
43 emotional and behavioural functioning). Mean total HoNOSCA score was 19.40 (± 8.17) on a
44 scale from 0 to 52, indicative of a severity similar to that at inpatient admission.^{21,22}
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 The proportion of the included sample notified from each region within the British Isles is
4 reported in Table 2, alongside the population of young people in each region by age. England has
5 the largest population (78%) and notified 70% of new cases. Scotland, containing only 7% of the
6 total population, notified 14% of the sample and Northern Ireland, containing only 3% of the
7 population, notified 13% of the sample. By contrast, the Republic of Ireland notified only 2% of
8 cases, despite containing 8% of the population, and Wales notified no eligible cases (some cases
9 were notified but did not meet inclusion criteria), despite containing 4% of the population.

16 17 ***Incidence rates***

18 Table 3 details observed incidence rates (IR0) and adjusted incidence rates (IR1 and IR2) by age.
19 Incidence rates for the total sample ranged from a minimum of 5.75 per 100,000 young people
20 (95% CI 5.23 to 6.30; IR0) to a maximum of 18.22 per 100,000 young people (95% CI 17.29 to
21 19.18; IR2), with IR1, the rate hypothesised to be the most accurate, falling between these two
22 values at 13.68 per 100,000 population (95% CI 12.88 to 14.52). Focusing on IR1 rates, total
23 incidence increased steadily with age, peaking at 16 (30.37, 95% CI 26.70 to 34.41), with a
24 substantial drop at the age of 17 (14.35, 95% CI 11.88 to 17.19).

25
26
27
28
29
30
31
32 Table 4 reports incidence rates by age and sex. Incidence among young men followed a similar
33 pattern to overall incidence rates reported in Table 3, being highest at the age of 16 (5.14) and
34 half that at age 17 (2.54). The highest incidence among young women was seen a year earlier
35 than for boys, at the age of 15 (57.77), with similar rates at age 16 (56.95), dropping by more
36 than half at age 17 (26.82).

37 38 39 40 41 42 **Discussion**

43 44 ***Principal findings***

45 This study provides up-to-date estimates of incident cases of anorexia nervosa in young people
46 aged 8 to 17 presenting to CAMHS services in the UK and Republic of Ireland. Our mid-range,
47 missing data-adjusted estimate (IR1) of the incidence of anorexia nervosa in the full sample of
48 young people aged 8 to 17 years was approximately 14 per 100,000.
49
50
51
52
53
54
55
56
57

Comparison with other studies

This result is lower than previous primary care-based estimates of 18–20 per 100,000 focusing on young people aged 10–19.^{2,5} This difference is due to the different age ranges in the studies; the inclusion of children as young as 8 in the current study, who have relatively low incidence, and exclusion of adolescents aged 18 to 19, whose incidence is relatively high, makes the results difficult to compare. However, comparing rates for 10 to 14-year olds, available in both studies, produces similar incidence rates, with rates of 12.6 per 100,000 in the current study, compared to 13.1 per 100,000 in 2009.² For females, the rates are 23.3 per 100,000 in the current study compared to 24.0 per 100,000 in 2009 and for males, 2.4 and 2.5 per 100,000, respectively. However, this comparison should be treated with caution given the very different settings – primary care versus secondary care.

Existing secondary care estimates of the incidence of anorexia nervosa in the UK are limited to children under the age of 13, with an overall incidence of 1.09 per 100,000 reported for children aged between 6 and 13 between 2005 and 2006.⁷ The methodology for this study was very similar to the CostED methodology, using the CAPSS system but additionally the British Paediatric Surveillance System. For comparison with the current study, the incidence rate for children between 8 and 13 was approximately 1.5 per 100,000 for DSMIV anorexia nervosa or 1.8 per 100,000 for DSMIV anorexia nervosa plus ‘other eating disorders’ likely to contain cases that would now be classified as anorexia nervosa using DSM5. This compares to a rate of 5.83 per 100,000 in the current study for children of the same age. This estimate is substantially higher than the 2006 estimates suggesting that incidence rates for younger children have increased over time.

Strengths and weaknesses of the study

The large, nationally representative sample of this study is a strength. It included young people with anorexia nervosa, diagnosed using DSM5 criteria, from across the UK and the Republic of Ireland and thus avoided biases inherent in studying clinical samples via a small number of centres in a limited number of geographical areas.

With only a 50% response rate from CAPSS clinicians and a third of questionnaires not returned, missing data were a constraint. There are many reasons why clinicians may fail to return

1
2
3 notification cards or questionnaires, including changes in place of employment, competing
4 priorities, or the belief that cases will be reported by a colleague.¹³ This problem was addressed
5 by adjusting the observed incidence rates using assumptions about incidence among both missing
6 case notifications and missing questionnaires.
7
8
9

10
11 The methodology is also limited to young people seen by child and adolescent psychiatrists.
12 Cases that would not be identified by this methodology include those who have not come to the
13 attention of services, those managed by general practitioners in primary care, and those in the
14 care of mental health services without psychiatric input, such as nurse-led facilities. This latter
15 concern was an issue in Northern Ireland where, due to initial low numbers of notifications,
16 investigation by the research team identified a number of nurse-led facilities which were invited
17 to contribute, and subsequently reported just over half of all cases in Northern Ireland. In terms
18 of missing primary care cases, given UK guidelines for assessment and diagnosis of anorexia
19 nervosa to be carried out by child and adolescent psychiatrists in secondary care settings,¹⁰ it is
20 reasonable to assume that many of those cases remaining in primary care would not meet criteria
21 for DSM5 anorexia nervosa.
22
23
24
25
26
27
28
29
30
31

32 ***Meaning of the study***

34 These results provide up-to-date estimates of the incidence of anorexia nervosa in young people.
35 Whilst firm conclusions relating to changes in incidence rates over time for the entire sample
36 cannot be drawn due to lack of existing secondary care evidence, service providers and
37 commissioners should consider evidence to suggest an increase in incidence in younger children.
38
39
40
41
42

43 ***Unanswered questions and future research***

44 Future research should explore the development of earlier interventions, given evidence of an
45 increase in incidence in young children suggesting that onset of anorexia nervosa may be starting
46 earlier for some young people than suggested by previous research. Research is also needed to
47 identify approaches to the assessment of incidence simultaneously in primary and secondary
48 care.
49
50
51
52
53
54
55
56
57
58
59
60

Word count

3686

Acknowledgements

The authors would like to thank all the clinicians who were kind enough to give up their time to provide the CostED study with CAPSS notifications and to complete questionnaires. We know your time is precious and in short supply and we are truly grateful. We would also like to thank the team at the Child and Adolescent Psychiatry Surveillance System, based at the Royal College of Psychiatrist's Centre for Care Quality and Improvement, for their support with the design and running of the surveillance aspect of this study. Finally, we would like to thank the members of the CostED study steering committee for their time and their support.

Contributors

SB was principal investigator, led the study and managed the King's College London research staff. GM managed the Northern Ireland research staff. SB and IE conceived the study. SB, IE, GM, MS, DN, TF, SG and BB designed the study. MS, DS, TF, IE, SG provided clinical expertise. DN and TF provided expertise on CAPSS methodology. HP, RS, NL and GK contributed to data collection, data entry and data cleaning. SB, HP, MP and BB carried out the data analysis. SB and HP drafted the manuscript. All authors have seen, commented on and approved the final version of the manuscript.

Funding

The study was funded by the NIHR Health Service & Delivery Research programme (11/1023/17). The study funders had no role in the study design, the collection, analysis or interpretation of data, the writing of the report, or the decision to submit the article for publication. The authors were independent from the funders and all authors had full access to all of the data in the study and can take responsibility for the integrity of the data and the accuracy of the data analysis.

Disclaimer

The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care.

Competing interests

TF reports she is Chair of the Child and Adolescent Psychiatry Surveillance Service that was used to run part of the study, which is an unpaid position (other than travel expenses). KJ reports that he was principal investigator for the Aberdeen site for a Sunovion sponsored multisite trial on effectiveness of Lurasidone in paediatric schizophrenia. No other authors report conflicts of interest.

Data sharing

No additional data available

References

- 1 Arcelus J, Mitchell AJ, Wales J, Nielsen S. Mortality rates in patients with anorexia nervosa and other eating disorders: A meta-analysis of 36 Studies. *Arch Gen Psychiatry* 2011;68:724–731.
- 2 Micali N, Hagberg KW, Petersen I, Treasure JL. The incidence of eating disorders in the UK in 2000-2009: findings from the General Practice Research Database. *BMJ Open* 2013;3:e002646.
- 3 Hoek HW. Incidence, prevalence and mortality of anorexia nervosa and other eating disorders. *Curr Opin Psychiatry* 2006;19:389–394.
- 4 Smink FRE, van Hoeken D, Hoek HW. Epidemiology of eating disorders: incidence, prevalence and mortality rates. *Current Psychiatry Reports* 2012;14:406–414.
- 5 Currin L, Schmidt U, Treasure J, Jick H. Time trends in eating disorder incidence. *Br J Psychiatry* 2005;186:132–135.
- 6 House J, Schmidt U, Craig M, et al. Comparison of specialist and nonspecialist care pathways for adolescents with anorexia nervosa and related eating disorders. *Int J Eat Disord* 2012;45:949–956.
- 7 Nicholls DE, Lynn R, Viner RM. Childhood eating disorders: British national surveillance study. *Br J Psychiatry* 2011;98:295–301.
- 8 Lask B, Bryant-Waugh R, Wright F, Campbell M, Willoughby K, Waller G. Family physician consultation patterns indicate high risk for early-onset anorexia nervosa. *Int J Eat Disord* 2005;38:269–272.
- 9 Goodman R, Ford T, Simmons H, Gatward R, Meltzer H. Using the Strengths and Difficulties Questionnaire (SDQ) to screen for child psychiatric disorders in a community sample. *Br J Psychiatry* 2000;177:534–539.
- 10 National Institute for Health and Care Excellence. Eating disorders: recognition and treatment. NICE guideline [NG69]. National Institute for Health and Care Excellence, 2017.
- 11 Byford S, Petkova H, Stuart R, et al. Cost-effectiveness of models of care for young people with eating disorders (the CostED study). *Health Service and Delivery Research* 2018 (in press).

- 1
2
3 12 Lynn RM, Viner RM, Nicholls DE. Ascertainment of early onset eating disorders: a pilot
4 for developing a national child psychiatric surveillance system. *Child Adolesc Ment*
5 *Health* 2012;17:109–112.
6
7
8 13 Knowles RL, Friend H, Lynn R, Mitchell S, Michie C, Ihekweazu C. Surveillance of rare
9 diseases: a public health evaluation of the British Paediatric Surveillance Unit. *J Public*
10 *Health* 2012;34:279–286.
11
12
13 14 American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders
14 (DSM–5), Fifth Edition. Washington DC: American Psychiatric Association, 2013.
15
16 15 Le Grange D, Doyle PM, Swanson SA, Ludwig K, Glunz K, Kreipe RE. Calculation of
17 expected body weight in adolescents with eating disorders. *Pediatrics* 2012;129:e438–
18 e446.
19
20
21
22 16 Gowers SG, Harrington RC, Whitton A, et al. Brief scale for measuring the outcomes of
23 emotional and behavioural disorders in children: Health of the Nation Outcome Scales for
24 Children and Adolescents (HoNOSCA). *Br J Psychiatry* 1999;174:413–416.
25
26
27 17 Shaffer D, Gould MS, Brasic J, et al. A children's global assessment scale (CGAS). *Arch*
28 *Gen Psychiatry* 1983;40:1228–1231.
29
30
31 18 Office for National Statistics. Population Estimates for UK, England and Wales, Scotland
32 and Northern Ireland. Office for National Statistics, 2015.
33
34 19 Central Statistics Office for the Republic of Ireland. PEA11: Population estimates from
35 1926 by Single Year of Age, Sex and Year,
36 [https://www.cso.ie/px/pxeirestat/Statire/SelectVarVal/Define.asp?maintable=PEA11&PL](https://www.cso.ie/px/pxeirestat/Statire/SelectVarVal/Define.asp?maintable=PEA11&PLanguage=0)
37 [anguage=0](https://www.cso.ie/px/pxeirestat/Statire/SelectVarVal/Define.asp?maintable=PEA11&PLanguage=0).
38
39
40
41 20 Hakulinen T, Dyba T. Precision of incidence predictions based on Poisson distributed
42 observations. *Stat Med* 1994;13:1513–1523.
43
44
45 21 Gowers S, Levine W, Bailey-Rogers S, Shore A, Burhouse E. Use of a routine, self-
46 report outcome measure (HoNOSCA-SR) in two adolescent mental health services. *Br J*
47 *Psychiatry* 2002;180:266–269.
48
49
50 22 Gowers SG, Clark A, Roberts C, et al. Clinical effectiveness of treatments for anorexia
51 nervosa in adolescents: Randomised controlled trial. *Br J Psychiatry* 2007;191:427–435.
52
53
54
55
56
57
58
59
60

Table 1 Characteristics of incident cases

	N	Mean (SD) or %
Age	305	14.56 (1.66)
Sex		
Female	279	91.48%
Male	26	8.52%
Ethnicity		
Any White	274	91.64%
White and Asian	6	2.01%
White and Black Caribbean	2	0.67%
White and Black African	1	0.33%
Other Mixed	1	0.33%
Indian	3	1.00%
Pakistani	2	0.67%
Bangladeshi	1	0.33%
Other Asian	4	1.34%
Black Caribbean	2	0.67%
Chinese	1	0.33%
Ethnicity not known	2	0.67%
Clinical status		
BMI	304	16.50 (2.25)
% of median expected BMI	303	83.23 (10.99)
CGAS	280	44.61 (14.08)
HoNOSCA	63	19.40 (8.17)

Table 2 Cases by region of the UK and Republic of Ireland

Region	Incident cases N	Incident cases %*	Population N	Population %
England	213	69.84%	6,194,444	77.83%
Scotland	44	14.43%	561,490	7.06%
Northern Ireland	41	13.44%	231,822	2.91%
Republic of Ireland	7	2.30%	628,251	7.89%
Wales	0	0.00%	342,627	4.31%
Total	305		7,958,634	

* Does not sum to 100 due to rounding

Table 3 Annual incidence of anorexia nervosa in young people aged 8 to 17 for 2015, reported per 100,000 young people

Age	Observed rate IR0		Adjusted rate IR1		Adjusted rate IR2	
	IR	95% CI	IR	95% CI	IR	95% CI
8	0.18	0.01 to 0.76	0.43	0.10 to 1.14	0.57	0.18 to 1.35
9	0.18	0.01 to 0.77	0.44	0.11 to 1.17	0.58	0.18 to 1.38
10	0.19	0.01 to 0.80	0.45	0.11 to 1.21	0.60	0.19 to 1.43
11	1.53	0.79 to 2.67	3.65	2.43 to 5.25	4.85	3.43 to 6.65
12	4.91	3.47 to 6.76	11.69	9.39 to 14.38	15.56	12.89 to 18.63
13	8.39	6.44 to 10.73	19.95	16.89 to 23.42	26.58	23.02 to 30.54
14	11.71	9.41 to 14.39	27.85	24.25 to 31.84	37.10	32.92 to 41.66
15	12.39	10.05 to 15.10	29.47	25.80 to 33.52	39.25	35.50 to 43.88
16	12.76	10.42 to 15.47	30.37	26.70 to 34.41	40.45	36.19 to 45.07
17	6.03	4.47 to 7.96	14.35	11.88 to 17.19	19.12	16.24 to 22.35
Total	5.75	5.23 to 6.30	13.68	12.88 to 14.52	18.22	17.29 to 19.18


Table 4 Annual incidence of anorexia nervosa in young people aged 8 to 17 for 2015 by sex, reported per 100,000 young people

Age	Observed incidence IR0				Adjusted incidence IR1				Adjusted incidence IR2			
	Female	95% CI	Male	95% CI	Female	95% CI	Male	95% CI	Female	95% CI	Male	95% CI
8	0.36	0.02 to 1.55	0.00	0.00 to 0.00	0.87	0.21 to 2.34	0.00	0.00 to 0.00	1.16	0.36 to 2.76	0.00	0.00 to 0.00
9	0.00	0.00 to 0.00	0.35	0.02 to 1.52	0.00	0.00 to 0.00	0.85	0.21 to 2.28	0.00	0.00 to 0.00	1.13	0.35 to 2.00
10	0.39	0.02 to 1.65	0.00	0.00 to 0.00	0.93	0.23 to 2.48	0.00	0.00 to 0.00	1.23	0.39 to 2.93	0.00	0.00 to 0.00
11	2.35	1.07 to 4.46	0.75	0.15 to 2.18	5.59	3.47 to 8.51	1.77	0.71 to 3.63	7.44	4.96 to 10.72	2.37	1.11 to 4.46
12	8.05	5.43 to 11.50	1.92	0.80 to 3.86	19.17	14.98 to 24.16	4.56	2.69 to 7.22	25.53	20.66 to 31.21	6.09	3.89 to 9.00
13	16.36	12.48 to 21.06	0.78	0.16 to 2.28	38.93	32.81 to 45.86	1.85	0.75 to 3.79	51.83	44.72 to 59.74	2.47	1.16 to 4.46
14	22.35	17.83 to 27.67	1.53	0.56 to 3.32	53.19	46.08 to 61.10	3.64	2.00 to 6.07	70.84	62.58 to 79.88	4.84	2.91 to 7.44
15	24.28	19.59 to 29.74	1.11	0.33 to 2.71	57.77	50.41 to 65.90	2.65	1.31 to 4.78	76.93	68.39 to 86.23	3.54	1.95 to 5.59
16	23.94	19.36 to 29.28	2.16	0.99 to 4.11	56.95	49.75 to 64.90	5.14	3.20 to 7.83	75.87	67.52 to 84.97	6.85	4.57 to 9.00
17	11.27	8.22 to 15.08	1.07	0.32 to 2.60	26.82	21.98 to 32.40	2.54	1.25 to 4.58	35.71	30.09 to 42.07	3.39	1.87 to 5.00
Total	10.78	9.77 to 11.87	0.96	0.68 to 1.30	25.66	24.09 to 27.30	2.28	1.84 to 2.79	34.17	32.36 to 36.06	3.03	2.52 to 3.00

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 1 Flow diagram of case ascertainment

For peer review only



Web extras

Case notification definition

Please report any child/young person aged 8 to 17 years and 11 months inclusive, who meets the case notification definition criteria below for the first time in the last month. One bullet point criterion from each group below should be fulfilled.

Group A

- Restriction of food, low body weight, or
- Weight less than expected for age

Group B

- Fear of gaining weight, or
- Fear of becoming fat, or
- Behaviour that interferes with weight gain, for example excessive exercising, self-induced vomiting, use of laxatives and diuretics

Group C

- Body image disturbance, or
- Persistent lack of recognition of the seriousness of the current low body weight

Exclusions

- Patients who are not underweight
- Patients with bulimia nervosa, binge eating disorder, avoidant restrictive food intake disorder or other failure to thrive presentations

STROBE Statement—Checklist of items that should be included in reports of *cross-sectional studies*

	Item No	Recommendation	Page No
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4
Objectives	3	State specific objectives, including any prespecified hypotheses	4
Methods			
Study design	4	Present key elements of study design early in the paper	4-5
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	4-5
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	5, 7
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	6, 7
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	6
Bias	9	Describe any efforts to address potential sources of bias	n/a
Study size	10	Explain how the study size was arrived at	n/a – population level
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	8-10
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	10
		(b) Describe any methods used to examine subgroups and interactions	n/a
		(c) Explain how missing data were addressed	8-9
		(d) If applicable, describe analytical methods taking account of sampling strategy	n/a
		(e) Describe any sensitivity analyses	n/a
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	10, 23
		(b) Give reasons for non-participation at each stage	10, 23
		(c) Consider use of a flow diagram	23
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	10-11, 19
		(b) Indicate number of participants with missing data for each	19

		variable of interest	
Outcome data	15*	Report numbers of outcome events or summary measures	n/a
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	11, 21-22
		(b) Report category boundaries when continuous variables were categorized	n/a
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	n/a
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	n/a
Discussion			
Key results	18	Summarise key results with reference to study objectives	12
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	12-13
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	13, 12
Generalisability	21	Discuss the generalisability (external validity) of the study results	13
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	15

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

Incidence of anorexia nervosa in young people in the United Kingdom and the Republic of Ireland: A national surveillance study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-027339.R1
Article Type:	Research
Date Submitted by the Author:	25-Mar-2019
Complete List of Authors:	Petkova, Hristina; Institute of Psychiatry Psychology and Neuroscience, Health Service and Population Research Department Simic, Mima; South London and Maudsley NHS Foundation Trust Nicholls, Dasha; Imperial College London Ford, Tamsin; University of Exeter Prina, A.Matthew; Institute of Psychiatry Psychology and Neuroscience Stuart, Ruth; Institute of Psychiatry Psychology and Neuroscience, Health Service and Population Research Department Livingstone, Nuala; Queen's University Belfast Kelly, Grace; Queen's University Belfast Macdonald, Geraldine; University of Bristol Eisler, Ivan; South London and Maudsley NHS Foundation Trust Gowers, Simon; University of Liverpool Barrett, Barbara; Institute of Psychiatry Psychology and Neuroscience Byford, Sarah; Institute of Psychiatry Psychology and Neuroscience
Primary Subject Heading:	Mental health
Secondary Subject Heading:	Epidemiology
Keywords:	Eating disorders < PSYCHIATRY, Child & adolescent psychiatry < PSYCHIATRY, EPIDEMIOLOGY, anorexia nervosa

SCHOLARONE™
Manuscripts

1
2
3 **Incidence of anorexia nervosa in young people in the United Kingdom and the Republic**
4 **of Ireland: A national surveillance study**

5
6 Hristina Petkova, Institute of Psychiatry, Psychology & Neuroscience at King's College
7 London (Research Fellow).

8
9
10 Mima Simic, South London and Maudsley NHS Foundation Trust (Consultant Child and
11 Adolescent Psychiatrist).

12
13 Dasha Nicholls, Imperial College London (Reader in Child and Adolescent Psychiatry).

14
15 Tamsin Ford, University of Exeter Medical School (Professor of Child and Adolescent
16 Psychiatry).

17
18 A. Matthew Prina, Institute of Psychiatry, Psychology & Neuroscience at King's College
19 London (Senior Lecturer in Epidemiology).

20
21 Ruth Stuart, Institute of Psychiatry, Psychology & Neuroscience at King's College London
22 (Research Assistant).

23
24 Nuala Livingstone, Queen's University Belfast (Research Fellow).

25
26 Grace Kelly, Queen's University Belfast (Research Fellow).

27
28 Geraldine Macdonald, University of Bristol (Professor of Social Work).

29
30 Ivan Eisler, South London and Maudsley NHS Foundation Trust (Professor of Family
31 Psychology and Family Therapy).

32
33 Simon Gowers, University of Liverpool (Professor of Adolescent Psychiatry).

34
35 Barbara Barrett, Institute of Psychiatry, Psychology & Neuroscience at King's College
36 London (Senior Lecturer in Health Economics).

37
38 Sarah Byford, Institute of Psychiatry, Psychology & Neuroscience at King's College London
39 (Professor of Health Economics).

40
41
42 Corresponding author: Sarah Byford, Institute of Psychiatry, Psychology & Neuroscience at
43 King's College London, P024 David Goldberg Centre, De Crespigny Park, London SE5 8AF,
44 UK, s.byford@kcl.ac.uk, 02078480043
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Objectives: This study aimed to estimate the incidence of DSM5 anorexia nervosa in young people in contact with child and adolescent mental health services in the UK and Republic of Ireland.

Design: Observational, surveillance study using the Child and Adolescent Psychiatry Surveillance System, involving monthly reporting by child and adolescent psychiatrists between 1st February 2015 and 30th September 2015.

Setting: UK and Republic of Ireland

Participants: Clinician-reported data on young people aged 8 to 17 in contact with child and adolescent mental health services for a first episode of anorexia nervosa.

Main outcome measures: Annual incidence rates estimated as confirmed new cases per 100,000 population at risk.

Results: 305 incident cases of anorexia nervosa were reported over the 8-month surveillance period and assessed as eligible for inclusion. The majority were young women (91%), from England (70%), and of white ethnicity (92%). Mean age was 14.6 years (± 1.66) and mean percentage of median expected BMI for age and sex was 83.23% ($\pm 10.99\%$). The overall incidence rate, adjusted for missing data, was estimated to be 13.68 per 100,000 population (95% CI 12.88 to 14.52), with rates of 25.66 for young women (95% CI 24.09 to 27.30) and 2.28 for young men (95% CI 1.84 to 2.79). Incidence increased steadily with age, peaking at 15 for young women (57.77, 95% CI 50.41 to 65.90) and 16 for young men (5.14, 95% CI 3.20 to 7.83). Comparison with earlier estimates suggests incidence rates for children aged 13 and under have increased over the last ten years.

Conclusions: These results provide up-to-date estimates of the incidence of anorexia nervosa in young people. Service providers and commissioners should consider evidence to suggest an increase in incidence in younger children.

Study registration: International Standard Randomised Controlled Trial Number Register [ISRCTN12676087].

Strengths and limitations of this study

- This study provides up-to-date estimates of the incidence of anorexia nervosa in young people aged 8 to 17 presenting to child and adolescent mental health services in the UK and Republic of Ireland.

- The study benefits from a large, nationally representative sample from across the UK and the Republic of Ireland.
- Results were limited by missing data which was dealt with by adjusting observed incidence rates using assumptions about incidence among missing cases.
- Results are relevant to young people diagnosed with anorexia nervosa by child and adolescent psychiatrists and not to those who are managed by general practitioners in primary care or those who have not come to the attention of services, for example those who choose not to seek help.

For peer review only

What is already known on this topic

Estimates of the incidence of anorexia nervosa in the UK and Republic of Ireland are at least ten years old. In addition, most estimates are derived from community-based primary care records, which fail to accurately record all new cases, since cases may present to accident and emergency and require immediate paediatric or psychiatric input, including inpatient admission. Existing incidence data from secondary care settings in the UK are limited and no data were identified for the Republic of Ireland. The only incidence study identified which used secondary care data – a British national surveillance study – focused only on children under 13 with data collected over ten years ago (2005-2006).

What this study adds

This study provides estimates of the incidence of DSM5 anorexia nervosa in young people aged 8 to 17 years in contact with child and adolescent mental health services in the United Kingdom and Republic of Ireland, which replace estimates that are over ten years old and limited by age range or geographical coverage. The results suggest that overall incidence rates have remained steady, but rates for young people under the age of 13 have increased over time. Providing up-to-date incidence estimates and monitoring trends can help to support health service planning for the provision of timely, effective and cost-effective interventions.

Introduction

Anorexia nervosa is a serious and enduring eating disorder with high morbidity and the highest mortality among psychiatric disorders.¹ Young women are particularly susceptible, with annual UK estimates of 37 new diagnoses of anorexia nervosa per 100,000 for girls aged 10 to 19 years, compared to 3 per 100,000 for boys of the same age.² Prevalence estimates in young people range from 0.3% to 0.6%.³⁻⁴

Accurate epidemiological estimates of the number of new anorexia nervosa cases per year and their sex and age profile are needed for causal investigations and service planning.² However, available estimates in the UK are at least ten years old.^{2,5-7} In addition, most estimates are derived from community-based primary care records,^{2,5} which fail to accurately record all new cases.^{8,9} Undetected anorexia nervosa cases may present to accident and emergency and require immediate paediatric or psychiatric input, including inpatient admission. Some young people may therefore bypass primary care and, consistent with UK guidelines,¹⁰ are likely to be assessed and diagnosed by a child and adolescent psychiatrist in a secondary care setting, making secondary care records a more reliable source of data on anorexia nervosa incidence than primary care registers.

Existing incidence data from secondary care settings in the UK are limited. One study, focusing only on adolescents aged 13 to 18, was limited to Greater London and reported presentation rates to child and adolescent mental health services (CAMHS), rather than incidence estimates.⁶ A second study, which used a national surveillance design, focused only on children under 13.⁷ The current study aimed to estimate the incidence of anorexia nervosa in secondary care services for young people between the ages of 8 and 17 years in the UK and the Republic of Ireland. This work formed part of a study exploring the cost-effectiveness of models of care for young people with eating disorders (the CostED study).¹¹

Methods

Design

An observational, surveillance study was undertaken using the Child and Adolescent Psychiatry Surveillance System (CAPSS). CAPSS is a system designed to ascertain cases of rare childhood mental health conditions in the UK and Republic of Ireland through monthly reporting by clinicians and relies on non-consent to maximise the accuracy of

1
2
3 epidemiological estimates. The CAPSS system has been operating since 2009¹² and is based
4 on the well-established British Paediatric Surveillance Unit (BPSU) system.¹³
5
6
7

8 The study was approved by the CAPSS Executive Committee, King's College London
9 Research Ethics Committee [PNM/13/14-105], and the Health Research Authority
10 Confidentiality Advisory Group [CAG 4-03(PR1)/2014] under Section 251 of the NHS Act
11 2006, which enables disclosure of confidential patient information for purposes where it is
12 not possible to use anonymised information and where seeking consent is not practical.
13
14
15
16
17

18 ***Inclusion and exclusion criteria***

19 The study included young people between 8 and 17 years of age, in contact with CAMHS for
20 a first episode of anorexia nervosa according to DSM5 diagnostic criteria.¹⁴ Anorexia
21 nervosa is exceptionally rare in children under 8 and the cut-off at 17 was due to the focus on
22 young people in contact with CAMHS, with many young people transitioning to adult
23 services at the age of 18. New cases were notified for a period of eight months from 1st
24 February to 30th September 2015. Cases whose clinician-reported data were insufficient to
25 assess eligibility were excluded, as were duplicate cases notified more than once by the same
26 or different clinicians.
27
28
29
30
31
32
33
34
35

36 ***Procedures***

37 At the time of the study, CAPSS used a report card, known as the yellow card, containing a
38 list of conditions being surveyed. Yellow cards, along with reporting instructions and
39 protocols for new studies, are sent monthly from the CAPSS office to a mailing list of all
40 hospital, university and community child and adolescent consultant psychiatrists across the
41 United Kingdom and the Republic of Ireland. Reporting clinicians are asked to check boxes
42 against any of the reportable conditions they have seen in the preceding month, or to check a
43 "nil return" box and return the card to CAPSS. A tear-off slip is provided for respondents to
44 keep a record of the patients reported. "Positive" returns are allocated a unique CAPSS ID
45 number and notified to the appropriate research investigator, who then contacts the reporting
46 clinician directly to request completion of a questionnaire using the CAPSS ID to enable the
47 clinician to identify the relevant patient.
48
49
50
51
52
53
54
55
56
57

58 For the CostED study, the yellow card contained a check box for anorexia nervosa and was
59 sent to clinicians along with a protocol card detailing the case notification definition for
60

1
2
3 anorexia nervosa. The case notification definition (see web extras) was based on DSM5
4 diagnostic criteria for anorexia nervosa and was intended to aid clinicians in their decision to
5 tick “yes” or “no” on the yellow card. It was not intended to identify whether a case met
6 study inclusion criteria, which was determined by the research group after receipt of all
7 necessary data.
8
9
10
11
12

13 ***Data***

14
15 Questionnaires were sent to clinicians who reported a positive case of anorexia nervosa,
16 identified via the unique CAPSS ID number. Questionnaires were completed from clinical
17 records and clinicians were asked to provide data relating to the time the case was initially
18 assessed and diagnosed. The questionnaire covered clinical features to enable assessment of
19 case eligibility, referral pathway information to ensure assessment and diagnosis had not
20 happened prior to the study surveillance period, and a limited set of standard patient
21 identifiers in line with CAPSS procedures and ethics requirements, which were used to
22 describe the sample and to identify duplicate notifications. In addition, clinicians were asked
23 to confirm whether the case was a first episode of anorexia nervosa that had come to the
24 attention of services.
25
26
27
28
29
30
31
32
33

34 The patient identifiers included NHS or Community Health Index (CHI) number (unique
35 patient identifiers used in the regions of interest), hospital number, first half of postcode or
36 town of residence for the Republic of Ireland, sex, date of birth and ethnicity (White, Mixed,
37 Asian, Black, Chinese, Other or Unknown). In Northern Ireland, identifiers were limited to
38 age in years and months and hospital identifier rather than hospital number, to reduce the risk
39 of patient identification given the small geographic area. All patient identifiable data from
40 Northern Ireland were retained by the local research team, de-duplicated, anonymised and
41 subsequently sent to the central research team in King’s College London for analysis as per
42 requirements set out by the Northern Ireland Privacy Advisory Committee. All data storage
43 was compliant with the EU General Data Protection Regulations.
44
45
46
47
48
49
50
51
52

53 Clinical features included: weight and height to calculate body mass index (BMI) and
54 percentage of median expected BMI for age and sex interpreted around the 85% threshold;¹⁵
55 the Health of the Nation Outcome Scales for Children and Adolescents (HoNOSCA¹⁶), a
56 routine outcome measure rating 13 clinical features on a five-point severity scale including
57 behaviours, impairments, symptoms, and social functioning of children and adolescents with
58
59
60

1
2
3 mental health problems; the clinician completed Children's Global Assessment Scale
4 (CGAS¹⁷) used to rate emotional and behavioural functioning of young people; and a range of
5 symptoms relating to the diagnosis of anorexia nervosa.
6
7
8
9

10 Unreturned or incomplete questionnaires were chased via email and telephone. Cases where
11 any symptom required for case definition was absent despite chasing, were assessed for
12 eligibility by a consultant child and adolescent psychiatrist (MS).
13
14
15

16 ***Case eligibility***

17 Cases were assessed as eligible for the study if: (a) they were between 8 and 17 years of age;
18 (b) they had no previous episode of anorexia nervosa that had come to the attention of
19 services; (c) they received a clinical assessment in the reporting service during the study
20 surveillance period; (d) they had not been referred from another secondary health service (to
21 ensure assessment and diagnosis had not happened prior to study surveillance period); and (e)
22 the following clinical symptoms were present: "Restriction of energy intake relative to
23 requirements" and "Persistent behaviour that interferes with weight gain, despite low
24 weight". This broad definition was subsequently checked using a tighter DSM5 analytic
25 definition including the following symptoms:
26
27
28
29
30
31
32
33

- 34 1) "Restriction of energy intake relative to requirements" and
- 35 2) "Intense fear of gaining weight or of becoming fat" or "Persistent behaviour that
36 interferes with weight gain, despite low weight" and
- 37 3) "Perception that body shape/size is larger than it is" or "Preoccupation with body
38 weight and shape" or "Lack of recognition of the seriousness of the current low body
39 weight"
40
41
42
43

44 Only one case which met the broad criteria failed to meet the tighter criteria, thus confirming
45 the validity of the broad criteria.
46
47
48
49

50 ***Removal of duplicates***

51 Duplicates were identified by comparing NHS/CHI numbers, hospital numbers/ hospital
52 identifiers and date of birth/age in years and months, as appropriate. The management of
53 duplicates depended upon the outcome for the original notification for which a duplicate was
54 identified. Four scenarios were considered: (1) duplicates where the original notification met
55 study inclusion criteria were excluded and the original retained; (2) duplicates where the
56 original notification had been excluded because the young person was under 8 years of age or
57
58
59
60

1
2
3 did not meet the clinical criteria were assessed as a new case to determine if the case now met
4 eligibility criteria; (3) duplicates where the original notification was excluded due to a
5 previous episode of anorexia nervosa, a diagnosis date prior to the study surveillance period
6 or referral from another secondary care service, were excluded; and (4) duplicates where the
7 original notification contained insufficient information to judge eligibility were checked to
8 see if the duplicate contained the missing information and, if available, the original
9 notification was reassessed for eligibility and the duplicate managed as per the scenarios
10 above.
11
12
13
14
15
16
17
18

19 **Data analysis**

20 Data analysis was performed using Stata IC v14.2 and Microsoft Excel 2010. Observed
21 incidence rates (denoted IR0), defined as the number of new cases during a specified period
22 of time in a population at risk for developing the disease, were calculated as follows: the
23 number of confirmed new cases of anorexia nervosa in the 8-month surveillance period
24 converted to 12 months [(N cases over 8 months/8)*12], divided by the population at risk and
25 multiplied by 100,000 to give the rate per 100,000 young people.
26
27
28
29
30
31
32

$$33 \text{ IR0} = (\text{confirmed new cases converted to 12 months}) / \text{the population at risk} * 100,000$$

34
35
36 The population at risk was calculated as the total number of children of each year of age and
37 each sex in the UK and Republic of Ireland minus the number of prevalent cases who, once
38 diagnosed, are no longer part of the “at risk” population. Population data for 2015 were
39 obtained from the Office for National Statistics for the UK¹⁸ and the Central Statistics Office
40 for the Republic of Ireland.¹⁹ To estimate the number of prevalent cases each year, incident
41 cases in the previous age band were used as a proxy. For example, incident cases aged eight
42 were used as a proxy for prevalent cases in the estimation of the ‘at risk’ population aged
43 nine, and so on.
44
45
46
47
48
49
50

51 To consider incidence among unobserved missing cases, adjustments were needed for
52 unreturned CAPSS notification cards and questionnaires. For CAPSS notification cards, just
53 over half of all notification cards sent out were returned (50.16%). To account for incidence
54 among the 49.84% of unreturned cards, two assumptions were made, and an appropriate
55 correction applied to IR0, the observed incidence rate:
56
57
58
59
60

1
2
3 *Assumption 1:* To take into consideration the possibility that unreturned cards are more likely
4 to be ‘nil’ returns, it was assumed that half of unreturned cards (24.92%) were ‘negative’ and
5 half followed the same proportion of ‘negative’ and ‘positive’ as the returned cards. This
6 assumption translates into a correction coefficient of 1.50 derived from $(24.92+50.16)/50.16$.
7
8
9

10
11 *Assumption 2:* Making no assumptions of bias in the likelihood of unreturned cards being
12 either positive or negative returns, it was assumed that all unreturned cards followed the same
13 proportion of ‘negative’ and ‘positive’ as returned cards. This assumption translates into a
14 correction coefficient of 1.99 derived from $(49.84+50.16)/50.16$.
15
16
17
18

19
20 These assumptions provide a range of incidence rates, from a minimum (observed incidence
21 rate) to a maximum (assumption 2), within which the actual rate is likely to fall. We
22 hypothesised that assumption 1 provides the most realistic estimate since it assumes a bias in
23 the response rates with greater likelihood that unreturned cards are negative (‘nil’ returns) but
24 does not assume *all* unreturned cards are ‘nil’ returns, which is the implicit assumption within
25 IR0.
26
27
28
29

30
31
32 For unreturned questionnaires, approximately two-thirds of the questionnaires that were sent
33 to clinicians reporting positive cases of anorexia nervosa were returned (63%), leaving one-
34 third (37%) unreturned. Since all these questionnaires relate to a ‘positive’ notification, we
35 applied a correction coefficient of 1.59 derived from $(37+63)/63$, which assumes that the
36 incidence rate for the unreturned questionnaires is the same as the incidence rate identified in
37 the returned questionnaires for each year of age.
38
39
40
41
42
43

44 We then combined the correction coefficients described above, to generate two adjusted
45 incidence rates:
46
47
48

49 *Adjusted incidence rate 1 (IR1)* = Confirmed new cases of anorexia nervosa converted to 12
50 months, multiplied by the correction for unreturned CAPSS notification cards under
51 assumption 1, multiplied by the correction for unreturned questionnaires, then divided by the
52 population at risk and multiplied by 100,000.
53
54
55
56

57
58
$$IR1 = (\text{confirmed new cases converted to 12 months} * 1.50 * 1.59) / \text{the population at risk}$$

59
$$*100,000$$

60

1
2
3
4
5 *Adjusted Incidence rate 2 (IR2)* = Confirmed new cases of anorexia nervosa converted to 12-
6 months, multiplied by the correction for unreturned CAPSS notification cards under
7 assumption 2, multiplied by the correction for unreturned questionnaires and then divided by
8 the population at risk and multiplied by 100,000.
9

$$10$$
$$11$$
$$12$$
$$13$$
$$14 \text{IR2} = (\text{confirmed new cases converted to 12 months} * 1.99 * 1.59) / \text{the population at risk} * \\ 15 \text{100,000}$$
$$16$$
$$17$$

18
19 For each incidence rate, IR0, IR1 and IR2, total, age-specific and sex-specific annual
20 incidence rates for anorexia nervosa for the year 2015 and 95% confidence intervals were
21 calculated based on the Poisson distribution²⁰ using the Stata command *ci means [N new*
22 *anorexia nervosa cases 12m], Poisson [exposure(total population)]* for positive
23 integers/whole incidence numbers (Stata interprets any non-integer decimal point number
24 between 0 and 1 as the fraction of events and converts it to an integer number). Annual
25 incidence rates were stratified by discrete age and sex.
26
27
28
29
30
31

32 ***Public and patient involvement statement***

33
34 The CostED study included a patient and a parent representative on the study steering
35 committee who contributed to the design, conduct and management of the study, including
36 the incidence component.
37
38
39

40 **Results**

41 ***Case ascertainment***

42
43 Case ascertainment is outlined in Figure 1. Over the eight-month surveillance period, 6401
44 yellow cards were sent to reporting clinicians and 3211 were returned (50%). Of these, 997
45 positive cases of anorexia nervosa were reported and 2214 were nil returns. Of the positive
46 cases, 48 (5%) were excluded due to clinicians stating that they did not wish to be included in
47 the study (due to retirement, shortage of reporting capacity etc.) or due to reporting errors.
48 Questionnaires were sent to the remaining 949, and a further 352 positive cases (37%) were
49 excluded as they failed to return the questionnaires, so no data were available to assess
50 eligibility. Questionnaires were completed and returned for 597 notified cases, of which 292
51 (49%) were ineligible for reasons related to age, previous episode of anorexia nervosa, date
52 of assessment outside the study's surveillance period, referral from another secondary care
53
54
55
56
57
58
59
60

1
2
3 service, insufficient information to assess diagnosis or duplicate notifications, leaving 305
4 incident cases of anorexia nervosa as the sample for analysis.
5
6
7

8 ***Demographics and clinical features***

9
10 Of the 305 young people identified as having DSM5 anorexia nervosa, the majority were
11 girls (91%), from England (70%) and of white ethnicity (92%) (see Table 1). The mean age
12 was 14.6 years (± 1.66). Clinical variables suggest these young people were significantly
13 impaired. Mean BMI was 16.50 kg/m² (± 2.25), where values of 16.00 to 16.99 suggesting
14 moderate severity of anorexia nervosa. Mean percentage of median expected BMI for age and
15 sex (the deviation from expected body weight) was 83.23% ($\pm 10.99\%$), falling within the
16 range required for a diagnosis of anorexia nervosa (<85%). Mean CGAS score was 44.61
17 (± 14.08), which falls within the range for 'obvious problems' (41–50) on a scale from 1 to
18 100 (1 being the worst and 100 the best emotional and behavioural functioning). Mean total
19 HoNOSCA score was 19.40 (± 8.17) on a scale from 0 to 52, indicative of a severity similar to
20 that at inpatient admission.^{21,22}
21
22
23
24
25
26
27
28
29

30
31 The proportion of the included sample notified from each region within the British Isles is
32 reported in Table 2, alongside the population of young people in each region by age. England
33 has the largest population (78%) and notified 70% of new cases. Scotland, containing only
34 7% of the total population, notified 14% of the sample and Northern Ireland, containing only
35 3% of the population, notified 13% of the sample. By contrast, the Republic of Ireland
36 notified only 2% of cases, despite containing 8% of the population, and Wales notified no
37 eligible cases (some cases were notified but did not meet inclusion criteria), despite
38 containing 4% of the population.
39
40
41
42
43
44
45

46 ***Incidence rates***

47
48 Table 3 details observed incidence rates (IR0) and adjusted incidence rates (IR1 and IR2) by
49 age. Incidence rates for the total sample ranged from a minimum of 5.75 per 100,000 young
50 people (95% CI 5.23 to 6.30; IR0) to a maximum of 18.22 per 100,000 young people (95%
51 CI 17.29 to 19.18; IR2), with IR1, the rate hypothesised to be the most accurate, falling
52 between these two values at 13.68 per 100,000 population (95% CI 12.88 to 14.52). Focusing
53 on IR1 rates, total incidence increased steadily with age, peaking at 16 (30.37, 95% CI 26.70
54 to 34.41), with a substantial drop at the age of 17 (14.35, 95% CI 11.88 to 17.19).
55
56
57
58
59
60

1
2
3 Table 4 reports incidence rates by age and sex. Incidence among young men followed a
4 similar pattern to overall incidence rates reported in Table 3, being highest at the age of 16
5 (5.14) and half that at age 17 (2.54). The highest incidence among young women was seen a
6 year earlier than for boys, at the age of 15 (57.77), with similar rates at age 16 (56.95),
7 dropping by more than half at age 17 (26.82).
8
9
10
11
12

13 **Discussion**

14 *Principal findings*

15 This study provides up-to-date estimates of incident cases of anorexia nervosa in young
16 people aged 8 to 17 presenting to CAMHS services in the UK and Republic of Ireland. Our
17 mid-range, missing data-adjusted estimate (IR1) of the incidence of anorexia nervosa in the
18 full sample of young people aged 8 to 17 years was approximately 14 per 100,000.
19
20
21
22
23
24
25

26 *Comparison with other studies*

27 This result is lower than previous primary care-based estimates of 18–20 per 100,000
28 focusing on young people aged 10–19.^{2,5} This difference is due to the different age ranges in
29 the studies; the inclusion of children as young as 8 in the current study, who have relatively
30 low incidence, and exclusion of adolescents aged 18 to 19, whose incidence is relatively high,
31 makes the results difficult to compare. However, comparing rates for 10 to 14-year olds,
32 available in both studies, produces similar incidence rates, with rates of 12.6 per 100,000 in
33 the current study, compared to 13.1 per 100,000 in 2009.² For females, the rates are 23.3 per
34 100,000 in the current study compared to 24.0 per 100,000 in 2009 and for males, 2.4 and 2.5
35 per 100,000, respectively. However, this comparison should be treated with caution given the
36 very different settings – primary care versus secondary care.
37
38
39
40
41
42
43
44
45

46 Existing secondary care estimates of the incidence of anorexia nervosa in the UK are limited
47 to children under the age of 13, with an overall incidence of 1.09 per 100,000 reported for
48 children aged between 6 and 13 between 2005 and 2006.⁷ The methodology for this study was
49 very similar to the CostED methodology, using the CAPSS system but additionally the British
50 Paediatric Surveillance System. For comparison with the current study, the incidence rate for
51 children between 8 and 13 was approximately 1.5 per 100,000 for DSMIV anorexia nervosa or
52 1.8 per 100,000 for DSMIV anorexia nervosa plus ‘other eating disorders’ likely to contain
53 cases that would now be classified as anorexia nervosa using DSM5. This compares to a rate
54 of 5.83 per 100,000 in the current study for children of the same age. This estimate is
55
56
57
58
59
60

1
2
3 substantially higher than the 2006 estimates suggesting that incidence rates for younger
4 children have increased over time.
5
6
7

8 The results presented are also supported by international evidence. One study carried out in
9 Italy demonstrated a significant reduction in age at onset for anorexia nervosa in consecutive
10 outpatient referrals between 1985 and 2008 (n=1,666).²³ A second study exploring time trends
11 in the incidence of anorexia nervosa, which was carried out using data from the Norwegian
12 National Patient Register, found overall rates of anorexia nervosa to be stable between 2010
13 and 2016 for the sample as a whole, but increasing for young females aged between 10 and
14 14.²⁴
15
16
17
18
19
20
21

22 ***Strengths and weaknesses of the study***

23 The large, nationally representative sample of this study is a strength. The study included
24 young people with anorexia nervosa, diagnosed using DSM5 criteria, from across the UK and
25 the Republic of Ireland and thus avoided biases inherent in studying clinical samples via a
26 small number of centres in a limited number of geographical areas. The results are of
27 relevance primarily to the UK and Republic of Ireland but may be of value to other high-
28 income countries.
29
30
31
32
33
34
35

36 With only a 50% response rate from CAPSS clinicians and a third of questionnaires not
37 returned, missing data were a major constraint. There are many reasons why clinicians may
38 fail to return notification cards or questionnaires, including changes in place of employment,
39 competing priorities, or the belief that cases will be reported by a colleague.¹³ This problem
40 was addressed by adjusting the observed incidence rates using assumptions about incidence
41 among both missing case notifications and missing questionnaires.
42
43
44
45
46
47

48 The methodology is also limited to young people seen by child and adolescent psychiatrists.
49 Cases that would not be identified by this methodology include those who have not come to
50 the attention of services, for example those who choose not to seek help, those managed by
51 general practitioners in primary care, and those in the care of mental health services without
52 psychiatric input, such as nurse-led facilities. This latter concern was an issue in Northern
53 Ireland where, due to initial low numbers of notifications, investigation by the research team
54 identified a number of nurse-led facilities which were invited to contribute, and subsequently
55 reported just over half of all cases in Northern Ireland. In terms of missing primary care
56
57
58
59
60

1
2
3 cases, given UK guidelines for assessment and diagnosis of anorexia nervosa to be carried
4 out by child and adolescent psychiatrists in secondary care settings,¹⁰ it is reasonable to
5 assume that many of those cases remaining in primary care would not meet criteria for DSM5
6 anorexia nervosa. It is also possible that current inpatient cases are under-represented;
7 although notifications were sent to all child and adolescent psychiatrists, including those
8 working in inpatient settings, the main focus of the CostED study was the evaluation of
9 community-based services, and so clinicians may have mistakenly focused on notification of
10 community-based cases.
11
12
13
14
15
16
17

18
19 It must also be borne in mind that service-level (rather than population-level) incidence rates
20 are sensitive to external factors, including service availability, funding and commissioning
21 decisions, parental and school awareness, stigma, etc., all of which will impact upon observed
22 trends in incidence rates over time. The nature of community-based eating disorders services
23 for children and adolescents in England has started to change following the publication of
24 commissioning standards in June 2015,²⁵ as well as investment of £30 million to support the
25 development of these services. This is unlikely to have had an impact on the CostED study
26 data because the first allocation of funding to services was made in 2016, after the end of the
27 CostED study surveillance period in 2015. However, these initiatives are likely to result in
28 increases in observed incidence rates in the future.
29
30
31
32
33
34
35
36

37 ***Meaning of the study***

38
39 These results provide up-to-date estimates of the incidence of anorexia nervosa in young
40 people. Whilst firm conclusions relating to changes in incidence rates over time for the entire
41 sample cannot be drawn due to lack of existing secondary care evidence, service providers
42 and commissioners should consider evidence to suggest an increase in incidence in younger
43 children.
44
45
46
47
48
49

50 ***Unanswered questions and future research***

51
52 Future research should explore the development of earlier interventions, given evidence of an
53 increase in incidence in young children suggesting that onset of anorexia nervosa may be
54 starting earlier for some young people than suggested by previous research. Research is also
55 needed to identify approaches to the assessment of incidence simultaneously in primary and
56 secondary care. Multinational studies should be considered for better assessment and
57 exploration of incidence rates in young men.
58
59
60

Word count

4089

Acknowledgements

We would like to thank all the clinicians who were kind enough to give up their time to provide the CostED study with CAPSS notifications and to complete questionnaires. We know your time is precious and in short supply and we are truly grateful. We would also like to thank the team at the Child and Adolescent Psychiatry Surveillance System, based at the Royal College of Psychiatrist's Centre for Care Quality and Improvement, for their support with the design and running of the surveillance aspect of this study, and the study steering committee for their invaluable advice.

Contributor and guarantor information

Hristina Petkova contributed to data collection, data entry, data cleaning, data analysis, and drafting of the manuscript.

Mima Simic was a co-applicant, contributed to the design of the study, provided clinical expertise, and commented on and approved the manuscript.

Dasha Nicholls was a co-applicant, contributed to the design of the study, provided expertise on CAPSS methodology, clinical expertise, and commented on and approved the manuscript.

Tamsin Ford was a co-applicant, contributed to the design of the study, provided clinical expertise, and commented on and approved the manuscript.

Matthew Prina contributed to the data analysis and commented on and approved the manuscript.

Ruth Stuart contributed to data collection, data entry, data cleaning and data analysis, and commented on and approved the manuscript.

Nuala Livingstone contributed to data collection, data entry and data management in Northern Ireland, and commented on and approved the manuscript.

Grace Kelly contributed to data collection, data entry and data management in Northern Ireland, and commented on and approved the manuscript.

Geraldine Macdonald contributed to the design of the study, managed the Northern Ireland research staff, and commented on and approved the final report.

Ivan Eisler was a co-applicant, contributed to the design of the study, provided clinical support to the research team, and commented on and approved the manuscript.

1
2
3 Simon Gowers was a co-applicant, contributed to the design of the study, provided clinical
4 expertise, and commented on and approved the manuscript.

5
6 Barbara Barrett was a co-applicant, contributed to the design of the study, the data analysis,
7 and commented on and approved the manuscript.

8
9 Sarah Byford was principal investigator, led the study, managed the King's College London
10 research staff, contributed to the design of the study and the data analysis, drafted the paper,
11 and is responsible for the overall content as guarantor.
12
13
14
15
16

17 **Competing interests**

18 Tamsin Ford reports she is Chair of the Child and Adolescent Psychiatry Surveillance Service
19 that was used to run part of the study, which is an unpaid position (other than travel
20 expenses). Kandarp Joshi reports that he was principal investigator for the Aberdeen site for a
21 Sunovion sponsored multisite trial on effectiveness of Lurasidone in paediatric schizophrenia.
22 No other authors report conflicts of interest.
23
24
25
26
27
28

29 **Transparency statement**

30 The lead author affirms that this manuscript is an honest, accurate, and transparent account of
31 the study being reported; that no important aspects of the study have been omitted; and that
32 any discrepancies from the study as planned and registered have been explained.
33
34
35
36
37

38 **Role of the funding source**

39 The study was funded by the NIHR Health Service & Delivery Research programme
40 (11/1023/17). The study funders had no role in the study design, the collection, analysis or
41 interpretation of data, the writing of the report, or the decision to submit the article for
42 publication. The authors were independent from the funders and all authors had full access to
43 all of the data in the study and can take responsibility for the integrity of the data and the
44 accuracy of the data analysis.
45
46
47
48
49
50

51 **Disclaimer**

52 The views expressed are those of the authors and not necessarily those of the NHS, the NIHR
53 or the Department of Health and Social Care.
54
55
56
57
58
59
60

Data sharing

As a result of the collection of confidential patient data without consent, and approval from the Health Research Authority (following advice from the Confidentiality Advisory Group) for data to be provided for the purposes of the specified activity only, the data cannot be made publicly available for other purposes. However, the CostED research group will consider requests for further analysis on a case by case basis, subject to appropriate ethical/HRA CAG approvals. All data enquiries should be submitted to the corresponding author for consideration in the first instance.

For peer review only

References

- 1 Arcelus J, Mitchell AJ, Wales J, Nielsen S. Mortality rates in patients with anorexia nervosa and other eating disorders: A meta-analysis of 36 Studies. *Arch Gen Psychiatry* 2011;68:724–731.
- 2 Micali N, Hagberg KW, Petersen I, Treasure JL. The incidence of eating disorders in the UK in 2000-2009: findings from the General Practice Research Database. *BMJ Open* 2013;3:e002646.
- 3 Hoek HW. Incidence, prevalence and mortality of anorexia nervosa and other eating disorders. *Curr Opin Psychiatry* 2006;19:389–394.
- 4 Smink FRE, van Hoeken D, Hoek HW. Epidemiology of eating disorders: incidence, prevalence and mortality rates. *Current Psychiatry Reports* 2012;14:406–414.
- 5 Currin L, Schmidt U, Treasure J, Jick H. Time trends in eating disorder incidence. *Br J Psychiatry* 2005;186:132–135.
- 6 House J, Schmidt U, Craig M, et al. Comparison of specialist and nonspecialist care pathways for adolescents with anorexia nervosa and related eating disorders. *Int J Eat Disord* 2012;45:949–956.
- 7 Nicholls DE, Lynn R, Viner RM. Childhood eating disorders: British national surveillance study. *Br J Psychiatry* 2011;98:295–301.
- 8 Lask B, Bryant-Waugh R, Wright F, Campbell M, Willoughby K, Waller G. Family physician consultation patterns indicate high risk for early-onset anorexia nervosa. *Int J Eat Disord* 2005;38:269–272.
- 9 Goodman R, Ford T, Simmons H, Gatward R, Meltzer H. Using the Strengths and Difficulties Questionnaire (SDQ) to screen for child psychiatric disorders in a community sample. *Br J Psychiatry* 2000;177:534–539.
- 10 National Institute for Health and Care Excellence. Eating disorders: recognition and treatment. NICE guideline [NG69]. National Institute for Health and Care Excellence, 2017.
- 11 Byford S, Petkova H, Stuart R, et al. Alternative community-based models of care for young people with anorexia nervosa: the CostED national surveillance study. *Health Service and Delivery Research* 2019 (in press).
- 12 Lynn RM, Viner RM, Nicholls DE. Ascertainment of early onset eating disorders: a pilot for developing a national child psychiatric surveillance system. *Child Adolesc Ment Health* 2012;17:109–112.

- 1
2
3 13 Knowles RL, Friend H, Lynn R, Mitchell S, Michie C, Ihekweazu C. Surveillance of
4 rare diseases: a public health evaluation of the British Paediatric Surveillance Unit. *J*
5 *Public Health* 2012;34:279–286.
6
7
8
9 14 American Psychiatric Association. Diagnostic and Statistical Manual of Mental
10 Disorders (DSM–5), Fifth Edition. Washington DC: American Psychiatric
11 Association, 2013.
12
13 15 Le Grange D, Doyle PM, Swanson SA, Ludwig K, Glunz K, Kreipe RE. Calculation
14 of expected body weight in adolescents with eating disorders. *Pediatrics*
15 2012;129:e438–e446.
16
17
18 16 Gowers SG, Harrington RC, Whitton A, et al. Brief scale for measuring the outcomes
19 of emotional and behavioural disorders in children: Health of the Nation Outcome
20 Scales for Children and Adolescents (HoNOSCA). *Br J Psychiatry* 1999;174:413–
21 416.
22
23
24 17 Shaffer D, Gould MS, Brasic J, et al. A children's global assessment scale (CGAS).
25 *Arch Gen Psychiatry* 1983;40:1228–1231.
26
27
28 18 Office for National Statistics. Population Estimates for UK, England and Wales,
29 Scotland and Northern Ireland. Office for National Statistics, 2015.
30
31
32 19 Central Statistics Office for the Republic of Ireland. PEA11: Population estimates
33 from 1926 by Single Year of Age, Sex and Year,
34 [https://www.cso.ie/px/pxeirestat/Statire/SelectVarVal/Define.asp?maintable=PEA11](https://www.cso.ie/px/pxeirestat/Statire/SelectVarVal/Define.asp?maintable=PEA11&PLanguage=0)
35 &PLanguage=0.
36
37
38 20 Hakulinen T, Dyba T. Precision of incidence predictions based on Poisson distributed
39 observations. *Stat Med* 1994;13:1513–1523.
40
41
42 21 Gowers S, Levine W, Bailey-Rogers S, Shore A, Burhouse E. Use of a routine, self-
43 report outcome measure (HoNOSCA-SR) in two adolescent mental health services.
44 *Br J Psychiatry* 2002;180:266–269.
45
46
47 22 Gowers SG, Clark A, Roberts C, et al. Clinical effectiveness of treatments for
48 anorexia nervosa in adolescents: Randomised controlled trial. *Br J Psychiatry*
49 2007;191:427–435.
50
51
52 23 Favaro A, Caregaro L, Tenconi E, Bosello R, Santonastaso P. Time trends in age at
53 onset of anorexia nervosa and bulimia nervosa. *J Clin Psychiatry* 2009;70:1715–1721
54
55
56 24 Reas DL, Rø O. Time trends in healthcare-detected incidence of anorexia nervosa and
57 bulimia nervosa in the Norwegian National Patient Register (2010–2016). *Int J Eat*
58 *Disord* 2018;51:1144–1152.
59
60

- 1
- 2
- 3
- 4 25 NHS England. Access and Waiting Time Standard for Children and Young People
- 5 with an Eating Disorder: Commissioning Guide. London: National Collaborating
- 6 Centre for Mental Health, 2015.
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

For peer review only

Table 1 Characteristics of incident cases

	N	Mean (SD) or %
Age	305	14.56 (1.66)
Sex		
Female	279	91.48%
Male	26	8.52%
Ethnicity		
Any White	274	91.64%
White and Asian	6	2.01%
White and Black Caribbean	2	0.67%
White and Black African	1	0.33%
Other Mixed	1	0.33%
Indian	3	1.00%
Pakistani	2	0.67%
Bangladeshi	1	0.33%
Other Asian	4	1.34%
Black Caribbean	2	0.67%
Chinese	1	0.33%
Ethnicity not known	2	0.67%
Clinical status		
BMI	304	16.50 (2.25)
% of median expected BMI	303	83.23 (10.99)
CGAS	280	44.61 (14.08)
HoNOSCA	63	19.40 (8.17)

Table 2 Cases by region of the UK and Republic of Ireland

Region	Incident cases N	Incident cases %*	Population N	Population %
England	213	69.84%	6,194,444	77.83%
Scotland	44	14.43%	561,490	7.06%
Northern Ireland	41	13.44%	231,822	2.91%
Republic of Ireland	7	2.30%	628,251	7.89%
Wales	0	0.00%	342,627	4.31%
Total	305		7,958,634	

* Does not sum to 100 due to rounding

Table 3 Annual incidence of anorexia nervosa in young people aged 8 to 17 for 2015, reported per 100,000 young people

Age	Observed rate IR0		Adjusted rate IR1		Adjusted rate IR2	
	IR	95% CI	IR	95% CI	IR	95% CI
8	0.18	0.01 to 0.76	0.43	0.10 to 1.14	0.57	0.18 to 1.35
9	0.18	0.01 to 0.77	0.44	0.11 to 1.17	0.58	0.18 to 1.38
10	0.19	0.01 to 0.80	0.45	0.11 to 1.21	0.60	0.19 to 1.43
11	1.53	0.79 to 2.67	3.65	2.43 to 5.25	4.85	3.43 to 6.65
12	4.91	3.47 to 6.76	11.69	9.39 to 14.38	15.56	12.89 to 18.63
13	8.39	6.44 to 10.73	19.95	16.89 to 23.42	26.58	23.02 to 30.54
14	11.71	9.41 to 14.39	27.85	24.25 to 31.84	37.10	32.92 to 41.66
15	12.39	10.05 to 15.10	29.47	25.80 to 33.52	39.25	35.50 to 43.88
16	12.76	10.42 to 15.47	30.37	26.70 to 34.41	40.45	36.19 to 45.07
17	6.03	4.47 to 7.96	14.35	11.88 to 17.19	19.12	16.24 to 22.35
Total	5.75	5.23 to 6.30	13.68	12.88 to 14.52	18.22	17.29 to 19.18

Table 4 Annual incidence of anorexia nervosa in young people aged 8 to 17 for 2015 by sex, reported per 100,000 young people

Age	Observed incidence IR0				Adjusted incidence IR1				Adjusted incidence IR2			
	Female	95% CI	Male	95% CI	Female	95% CI	Male	95% CI	Female	95% CI	Male	95% CI
8	0.36	0.02 to 1.55	0.00	0.00 to 0.00	0.87	0.21 to 2.34	0.00	0.00 to 0.00	1.16	0.36 to 2.76	0.00	0.00 to 0.00
9	0.00	0.00 to 0.00	0.35	0.02 to 1.52	0.00	0.00 to 0.00	0.85	0.21 to 2.28	0.00	0.00 to 0.00	1.13	0.35 to 2.69
10	0.39	0.02 to 1.65	0.00	0.00 to 0.00	0.93	0.23 to 2.48	0.00	0.00 to 0.00	1.23	0.39 to 2.93	0.00	0.00 to 0.00
11	2.35	1.07 to 4.46	0.75	0.15 to 2.18	5.59	3.47 to 8.51	1.77	0.71 to 3.63	7.44	4.96 to 10.72	2.37	1.11 to 4.42
12	8.05	5.43 to 11.50	1.92	0.80 to 3.86	19.17	14.98 to 24.16	4.56	2.69 to 7.22	25.53	20.66 to 31.21	6.09	3.89 to 9.08
13	16.36	12.48 to 21.06	0.78	0.16 to 2.28	38.93	32.81 to 45.86	1.85	0.75 to 3.79	51.83	44.72 to 59.74	2.47	1.16 to 4.62
14	22.35	17.83 to 27.67	1.53	0.56 to 3.32	53.19	46.08 to 61.10	3.64	2.00 to 6.07	70.84	62.58 to 79.88	4.84	2.91 to 7.55
15	24.28	19.59 to 29.74	1.11	0.33 to 2.71	57.77	50.41 to 65.90	2.65	1.31 to 4.78	76.93	68.39 to 86.23	3.54	1.95 to 5.91
16	23.94	19.36 to 29.28	2.16	0.99 to 4.11	56.95	49.75 to 64.90	5.14	3.20 to 7.83	75.87	67.52 to 84.97	6.85	4.57 to 9.87
17	11.27	8.22 to 15.08	1.07	0.32 to 2.60	26.82	21.98 to 32.40	2.54	1.25 to 4.58	35.71	30.09 to 42.07	3.39	1.87 to 5.67
Total	10.78	9.77 to 11.87	0.96	0.68 to 1.30	25.66	24.09 to 27.30	2.28	1.84 to 2.79	34.17	32.36 to 36.06	3.03	2.52 to 3.62

1
2
3 **Figure legends**
4
5

6 Figure 1 Flow diagram of case ascertainment
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Web extras

Case notification definition

Please report any child/young person aged 8 to 17 years and 11 months inclusive, who meets the case notification definition criteria below for the first time in the last month. One bullet point criterion from each group below should be fulfilled.

Group A

- Restriction of food, low body weight, or
- Weight less than expected for age

Group B


- Fear of gaining weight, or
- Fear of becoming fat, or
- Behaviour that interferes with weight gain, for example excessive exercising, self-induced vomiting, use of laxatives and diuretics

Group C

- Body image disturbance, or
- Persistent lack of recognition of the seriousness of the current low body weight

Exclusions

- Patients who are not underweight
- Patients with bulimia nervosa, binge eating disorder, avoidant restrictive food intake disorder or other failure to thrive presentations



STROBE Statement—Checklist of items that should be included in reports of *cross-sectional studies*

	Item No	Recommendation	Page No
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	5
Objectives	3	State specific objectives, including any prespecified hypotheses	5
Methods			
Study design	4	Present key elements of study design early in the paper	5-6
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	5 (setting, location), 6 (dates), 7-8 (data)
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	6 (eligibility), 8 (selection)
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	7-8 (outcomes), 8 (diagnostic criteria)
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	7-8
Bias	9	Describe any efforts to address potential sources of bias	10, 14
Study size	10	Explain how the study size was arrived at	n/a – population level
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	9-11
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	11
		(b) Describe any methods used to examine subgroups and interactions	n/a
		(c) Explain how missing data were addressed	9-11
		(d) If applicable, describe analytical methods taking account of sampling strategy	n/a
		(e) Describe any sensitivity analyses	n/a
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	11, Figure 1
		(b) Give reasons for non-participation at each stage	11, Figure 1
		(c) Consider use of a flow diagram	Figure 1

Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	12, 22 (Table 1)
		(b) Indicate number of participants with missing data for each variable of interest	22 (Table 1)
Outcome data	15*	Report numbers of outcome events or summary measures	n/a
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	12-13, 24-25 (Tables 3 & 4)
		(b) Report category boundaries when continuous variables were categorized	n/a
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	n/a
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	n/a
Discussion			
Key results	18	Summarise key results with reference to study objectives	13
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	14-15
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	15 (interpretation), 13-14 (comparison with similar studies)
Generalisability	21	Discuss the generalisability (external validity) of the study results	14
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	17

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

Incidence of anorexia nervosa in young people in the United Kingdom and the Republic of Ireland: A national surveillance study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-027339.R2
Article Type:	Research
Date Submitted by the Author:	18-Jul-2019
Complete List of Authors:	Petkova, Hristina; Institute of Psychiatry Psychology and Neuroscience, Health Service and Population Research Department Simic, Mima; South London and Maudsley NHS Foundation Trust Nicholls, Dasha; Imperial College London Ford, Tamsin; University of Exeter Prina, A.Matthew; Institute of Psychiatry Psychology and Neuroscience Stuart, Ruth; Institute of Psychiatry Psychology and Neuroscience, Health Service and Population Research Department Livingstone, Nuala; Queen's University Belfast Kelly, Grace; Queen's University Belfast Macdonald, Geraldine; University of Bristol Eisler, Ivan; South London and Maudsley NHS Foundation Trust Gowers, Simon; University of Liverpool Barrett, Barbara; Institute of Psychiatry Psychology and Neuroscience Byford, Sarah; Institute of Psychiatry Psychology and Neuroscience
Primary Subject Heading:	Mental health
Secondary Subject Heading:	Epidemiology
Keywords:	Eating disorders < PSYCHIATRY, Child & adolescent psychiatry < PSYCHIATRY, EPIDEMIOLOGY, anorexia nervosa

SCHOLARONE™
Manuscripts

1
2
3 **Incidence of anorexia nervosa in young people in the United Kingdom and the Republic**
4 **of Ireland: A national surveillance study**

5
6 Hristina Petkova, Institute of Psychiatry, Psychology & Neuroscience at King's College
7 London (Research Fellow).

8
9
10 Mima Simic, South London and Maudsley NHS Foundation Trust (Consultant Child and
11 Adolescent Psychiatrist).

12
13 Dasha Nicholls, Imperial College London (Reader in Child and Adolescent Psychiatry).

14
15 Tamsin Ford, University of Exeter Medical School (Professor of Child and Adolescent
16 Psychiatry).

17
18 A. Matthew Prina, Institute of Psychiatry, Psychology & Neuroscience at King's College
19 London (Senior Lecturer in Epidemiology).

20
21 Ruth Stuart, Institute of Psychiatry, Psychology & Neuroscience at King's College London
22 (Research Assistant).

23
24 Nuala Livingstone, Queen's University Belfast (Research Fellow).

25
26 Grace Kelly, Queen's University Belfast (Research Fellow).

27
28 Geraldine Macdonald, University of Bristol (Professor of Social Work).

29
30 Ivan Eisler, South London and Maudsley NHS Foundation Trust (Professor of Family
31 Psychology and Family Therapy).

32
33 Simon Gowers, University of Liverpool (Professor of Adolescent Psychiatry).

34
35 Barbara Barrett, Institute of Psychiatry, Psychology & Neuroscience at King's College
36 London (Senior Lecturer in Health Economics).

37
38 Sarah Byford, Institute of Psychiatry, Psychology & Neuroscience at King's College London
39 (Professor of Health Economics).

40
41
42
43
44 Corresponding author: Sarah Byford, Institute of Psychiatry, Psychology & Neuroscience at
45 King's College London, P024 David Goldberg Centre, De Crespigny Park, London SE5 8AF,
46 UK, s.byford@kcl.ac.uk, 02078480043
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Objectives: This study aimed to estimate the incidence of DSM5 anorexia nervosa in young people in contact with child and adolescent mental health services in the UK and Republic of Ireland.

Design: Observational, surveillance study using the Child and Adolescent Psychiatry Surveillance System, involving monthly reporting by child and adolescent psychiatrists between 1st February 2015 and 30th September 2015.

Setting: UK and Republic of Ireland

Participants: Clinician-reported data on young people aged 8 to 17 in contact with child and adolescent mental health services for a first episode of anorexia nervosa.

Main outcome measures: Annual incidence rates estimated as confirmed new cases per 100,000 population at risk.

Results: 305 incident cases of anorexia nervosa were reported over the 8-month surveillance period and assessed as eligible for inclusion. The majority were young women (91%), from England (70%), and of white ethnicity (92%). Mean age was 14.6 years (± 1.66) and mean percentage of median expected BMI for age and sex was 83.23% ($\pm 10.99\%$). The overall incidence rate, adjusted for missing data, was estimated to be 13.68 per 100,000 population (95% CI 12.88 to 14.52), with rates of 25.66 for young women (95% CI 24.09 to 27.30) and 2.28 for young men (95% CI 1.84 to 2.79). Incidence increased steadily with age, peaking at 15 for young women (57.77, 95% CI 50.41 to 65.90) and 16 for young men (5.14, 95% CI 3.20 to 7.83). Comparison with earlier estimates suggests incidence rates for children aged 13 and under have increased over the last ten years.

Conclusions: These results provide new estimates of the incidence of anorexia nervosa in young people. Service providers and commissioners should consider evidence to suggest an increase in incidence in younger children.

Study registration: International Standard Randomised Controlled Trial Number Register [ISRCTN12676087].

Strengths and limitations of this study

- The study benefits from a large, nationally representative sample from across the UK and the Republic of Ireland.

- This study used a National surveillance system to collect data and thus avoided biases inherent in studying clinical samples via a small number of centres in a limited number of geographical areas.
- Results were limited by missing data which was dealt with by adjusting observed incidence rates using assumptions about incidence among missing cases.
- Results are relevant to young people diagnosed with anorexia nervosa by child and adolescent psychiatrists and not to those who are managed by general practitioners in primary care or those who have not come to the attention of services, for example those who choose not to seek help.

For peer review only

Introduction

Anorexia nervosa is a serious and enduring eating disorder with high morbidity and the highest mortality among psychiatric disorders.¹ Young women are particularly susceptible, with annual UK estimates of 37 new diagnoses of anorexia nervosa per 100,000 for girls aged 10 to 19 years, compared to 3 per 100,000 for boys of the same age.² Prevalence estimates in young people range from 0.3% to 0.6%.³⁻⁴

Accurate epidemiological estimates of the number of new anorexia nervosa cases per year and their sex and age profile are needed for causal investigations and service planning.² However, available estimates in the UK are at least ten years old.^{2,5-7} In addition, most estimates are derived from community-based primary care records,^{2,5} which fail to accurately record all new cases.^{8,9} Undetected anorexia nervosa cases may present to accident and emergency and require immediate paediatric or psychiatric input, including inpatient admission. Some young people may therefore bypass primary care and, consistent with UK guidelines,¹⁰ are likely to be assessed and diagnosed by a child and adolescent psychiatrist in a secondary care setting, making secondary care records a more reliable source of data on anorexia nervosa incidence than primary care registers.

Existing incidence data from secondary care settings in the UK are limited. One study, focusing only on adolescents aged 13 to 18, was limited to Greater London and reported presentation rates to child and adolescent mental health services (CAMHS), rather than incidence estimates.⁶ A second study, which used a national surveillance design, focused only on children under 13.⁷ The current study aimed to estimate the incidence of anorexia nervosa in secondary care services for young people between the ages of 8 and 17 years in the UK and the Republic of Ireland. This work formed part of a study exploring the cost-effectiveness of models of care for young people with eating disorders (the CostED study).¹¹

Methods

Design

An observational, surveillance study was undertaken using the Child and Adolescent Psychiatry Surveillance System (CAPSS). CAPSS is a system designed to ascertain cases of rare childhood mental health conditions in the UK and Republic of Ireland through monthly reporting by clinicians and relies on non-consent to maximise the accuracy of

1
2
3 epidemiological estimates. The CAPSS system has been operating since 2009¹² and is based
4 on the well-established British Paediatric Surveillance Unit (BPSU) system.¹³
5
6
7

8 The study was approved by the CAPSS Executive Committee, King's College London
9 Research Ethics Committee [PNM/13/14-105], and the Health Research Authority [CAG 4-
10 03(PR1)/2014] under Section 251 of the NHS Act 2006, which enables disclosure of
11 confidential patient information for purposes where it is not possible to use anonymised
12 information and where seeking consent is not practical.
13
14
15
16
17

18 ***Inclusion and exclusion criteria***

19 The study included young people between 8 and 17 years of age, in contact with CAMHS for
20 a first episode of anorexia nervosa according to DSM5 diagnostic criteria.¹⁴ Anorexia
21 nervosa is exceptionally rare in children under 8 and the cut-off at 17 was due to the focus on
22 young people in contact with CAMHS, with many young people transitioning to adult
23 services at the age of 18. New cases were notified for a period of eight months from 1st
24 February to 30th September 2015. Cases whose clinician-reported data were insufficient to
25 assess eligibility were excluded, as were duplicate cases notified more than once by the same
26 or different clinicians.
27
28
29
30
31
32
33
34
35

36 ***Procedures***

37 At the time of the study, CAPSS used a report card, known as the yellow card, containing a
38 list of conditions being surveyed. Yellow cards, along with reporting instructions and
39 protocols for new studies, are sent monthly from the CAPSS office to a mailing list of all
40 hospital, university and community child and adolescent consultant psychiatrists across the
41 United Kingdom and the Republic of Ireland. Reporting clinicians are asked to check boxes
42 against any of the reportable conditions they have seen in the preceding month, or to check a
43 "nil return" box and return the card to CAPSS. A tear-off slip is provided for respondents to
44 keep a record of the patients reported. "Positive" returns are allocated a unique CAPSS ID
45 number and notified to the appropriate research investigator, who then contacts the reporting
46 clinician directly to request completion of a questionnaire using the CAPSS ID to enable the
47 clinician to identify the relevant patient.
48
49
50
51
52
53
54
55
56
57

58 For the CostED study, the yellow card contained a check box for anorexia nervosa and was
59 sent to clinicians along with a protocol card detailing the case notification definition for
60

1
2
3 anorexia nervosa. The case notification definition (see web extras) was based on DSM5
4 diagnostic criteria for anorexia nervosa and was intended to aid clinicians in their decision to
5 tick “yes” or “no” on the yellow card. It was not intended to identify whether a case met
6 study inclusion criteria, which was determined by the research group after receipt of all
7 necessary data.
8
9
10
11
12

13 ***Data***

14
15 Questionnaires were sent to clinicians who reported a positive case of anorexia nervosa,
16 identified via the unique CAPSS ID number. Questionnaires were completed from clinical
17 records and clinicians were asked to provide data relating to the time the case was initially
18 assessed and diagnosed. The questionnaire covered clinical features to enable assessment of
19 case eligibility, referral pathway information to ensure assessment and diagnosis had not
20 happened prior to the study surveillance period, and a limited set of standard patient
21 identifiers in line with CAPSS procedures and ethics requirements, which were used to
22 describe the sample and to identify duplicate notifications. In addition, clinicians were asked
23 to confirm whether the case was a first episode of anorexia nervosa that had come to the
24 attention of services.
25
26
27
28
29
30
31
32
33

34 The patient identifiers included NHS or Community Health Index (CHI) number (unique
35 patient identifiers used in the regions of interest), hospital number, first half of postcode or
36 town of residence for the Republic of Ireland, sex, date of birth and ethnicity (White, Mixed,
37 Asian, Black, Chinese, Other or Unknown). In Northern Ireland, identifiers were limited to
38 age in years and months and hospital identifier rather than hospital number, to reduce the risk
39 of patient identification given the small geographic area. All patient identifiable data from
40 Northern Ireland were retained by the local research team, de-duplicated, anonymised and
41 subsequently sent to the central research team in King’s College London for analysis as per
42 requirements set out by the Northern Ireland Privacy Advisory Committee. All data storage
43 was compliant with the EU General Data Protection Regulations.
44
45
46
47
48
49
50
51
52

53 Clinical features included: weight and height to calculate body mass index (BMI) and
54 percentage of median expected BMI for age and sex interpreted around the 85% threshold;¹⁵
55 the Health of the Nation Outcome Scales for Children and Adolescents (HoNOSCA¹⁶), a
56 routine outcome measure rating 13 clinical features on a five-point severity scale including
57 behaviours, impairments, symptoms, and social functioning of children and adolescents with
58
59
60

1
2
3 mental health problems; the clinician completed Children's Global Assessment Scale
4 (CGAS¹⁷) used to rate emotional and behavioural functioning of young people; and a range of
5 symptoms relating to the diagnosis of anorexia nervosa.
6
7
8
9

10 Unreturned or incomplete questionnaires were chased via email and telephone. Cases where
11 any symptom required for case definition was absent despite chasing, were assessed for
12 eligibility by a consultant child and adolescent psychiatrist (MS).
13
14
15

16 ***Case eligibility***

17 Cases were assessed as eligible for the study if: (a) they were between 8 and 17 years of age;
18 (b) they had no previous episode of anorexia nervosa that had come to the attention of
19 services; (c) they received a clinical assessment in the reporting service during the study
20 surveillance period; (d) they had not been referred from another secondary health service (to
21 ensure assessment and diagnosis had not happened prior to study surveillance period); and (e)
22 the following clinical symptoms were present: "Restriction of energy intake relative to
23 requirements" and "Persistent behaviour that interferes with weight gain, despite low
24 weight". This broad definition was subsequently checked using a tighter DSM5 analytic
25 definition including the following symptoms:
26
27
28
29
30
31
32
33

- 34 1) "Restriction of energy intake relative to requirements" and
- 35 2) "Intense fear of gaining weight or of becoming fat" or "Persistent behaviour that
36 interferes with weight gain, despite low weight" and
- 37 3) "Perception that body shape/size is larger than it is" or "Preoccupation with body
38 weight and shape" or "Lack of recognition of the seriousness of the current low body
39 weight"
40
41
42
43

44 Only one case which met the broad criteria failed to meet the tighter criteria, thus confirming
45 the validity of the broad criteria.
46
47
48
49

50 ***Removal of duplicates***

51 Duplicates were identified by comparing NHS/CHI numbers, hospital numbers/ hospital
52 identifiers and date of birth/age in years and months, as appropriate. The management of
53 duplicates depended upon the outcome for the original notification for which a duplicate was
54 identified. Four scenarios were considered: (1) duplicates where the original notification met
55 study inclusion criteria were excluded and the original retained; (2) duplicates where the
56 original notification had been excluded because the young person was under 8 years of age or
57
58
59
60

1
2
3 did not meet the clinical criteria were assessed as a new case to determine if the case now met
4 eligibility criteria; (3) duplicates where the original notification was excluded due to a
5 previous episode of anorexia nervosa, a diagnosis date prior to the study surveillance period
6 or referral from another secondary care service, were excluded; and (4) duplicates where the
7 original notification contained insufficient information to judge eligibility were checked to
8 see if the duplicate contained the missing information and, if available, the original
9 notification was reassessed for eligibility and the duplicate managed as per the scenarios
10 above.
11
12
13
14
15
16
17
18

19 **Data analysis**

20 Data analysis was performed using Stata IC v14.2 and Microsoft Excel 2010. Observed
21 incidence rates (denoted IR0), defined as the number of new cases during a specified period
22 of time in a population at risk for developing the disease, were calculated as follows: the
23 number of confirmed new cases of anorexia nervosa in the 8-month surveillance period
24 converted to 12 months [(N cases over 8 months/8)*12], divided by the population at risk and
25 multiplied by 100,000 to give the rate per 100,000 young people.
26
27
28
29
30
31
32

$$33 \text{ IR0} = (\text{confirmed new cases converted to 12 months}) / \text{the population at risk} * 100,000$$

34
35
36 The population at risk was calculated as the total number of children of each year of age and
37 each sex in the UK and Republic of Ireland minus the number of prevalent cases who, once
38 diagnosed, are no longer part of the “at risk” population. Population data for 2015 were
39 obtained from the Office for National Statistics for the UK¹⁸ and the Central Statistics Office
40 for the Republic of Ireland.¹⁹ To estimate the number of prevalent cases each year, incident
41 cases in the previous age band were used as a proxy. For example, incident cases aged eight
42 were used as a proxy for prevalent cases in the estimation of the ‘at risk’ population aged
43 nine, and so on.
44
45
46
47
48
49
50

51 To consider incidence among unobserved missing cases, adjustments were needed for
52 unreturned CAPSS notification cards and questionnaires. For CAPSS notification cards, just
53 over half of all notification cards sent out were returned (50.16%). To account for incidence
54 among the 49.84% of unreturned cards, two assumptions were made, and an appropriate
55 correction applied to IR0, the observed incidence rate:
56
57
58
59
60

1
2
3 *Assumption 1:* To take into consideration the possibility that unreturned cards are more likely
4 to be 'nil' returns, it was assumed that half of unreturned cards (24.92%) were 'negative' and
5 half followed the same proportion of 'negative' and 'positive' as the returned cards. This
6 assumption translates into a correction coefficient of 1.50 derived from $(24.92+50.16)/50.16$.
7
8
9

10
11 *Assumption 2:* Making no assumptions of bias in the likelihood of unreturned cards being
12 either positive or negative returns, it was assumed that all unreturned cards followed the same
13 proportion of 'negative' and 'positive' as returned cards. This assumption translates into a
14 correction coefficient of 1.99 derived from $(49.84+50.16)/50.16$.
15
16
17
18
19

20 These assumptions provide a range of incidence rates, from a minimum (observed incidence
21 rate) to a maximum (assumption 2), within which the actual rate is likely to fall. We
22 hypothesised that assumption 1 provides the most realistic estimate since it assumes a bias in
23 the response rates with greater likelihood that unreturned cards are negative ('nil' returns) but
24 does not assume *all* unreturned cards are 'nil' returns, which is the implicit assumption within
25 IR0.
26
27
28
29
30

31
32 For unreturned questionnaires, approximately two-thirds of the questionnaires that were sent
33 to clinicians reporting positive cases of anorexia nervosa were returned (63%), leaving one-
34 third (37%) unreturned. Since all these questionnaires relate to a 'positive' notification, we
35 applied a correction coefficient of 1.59 derived from $(37+63)/63$, which assumes that the
36 incidence rate for the unreturned questionnaires is the same as the incidence rate identified in
37 the returned questionnaires for each year of age.
38
39
40
41
42
43

44 We then combined the correction coefficients described above, to generate two adjusted
45 incidence rates:
46
47
48
49

50 *Adjusted incidence rate 1 (IR1)* = Confirmed new cases of anorexia nervosa converted to 12
51 months, multiplied by the correction for unreturned CAPSS notification cards under
52 assumption 1, multiplied by the correction for unreturned questionnaires, then divided by the
53 population at risk and multiplied by 100,000.
54
55
56
57

58 $IR1 = (\text{confirmed new cases converted to 12 months} * 1.50 * 1.59) / \text{the population at risk}$
59 $* 100,000$
60

1
2
3
4
5 *Adjusted Incidence rate 2 (IR2)* = Confirmed new cases of anorexia nervosa converted to 12-
6 months, multiplied by the correction for unreturned CAPSS notification cards under
7 assumption 2, multiplied by the correction for unreturned questionnaires and then divided by
8 the population at risk and multiplied by 100,000.
9

$$10$$
$$11$$
$$12$$
$$13$$
$$14 \text{ IR2} = (\text{confirmed new cases converted to 12 months} * 1.99 * 1.59) / \text{the population at risk} * \\ 15 \text{ 100,000}$$
$$16$$
$$17$$

18
19 For each incidence rate, IR0, IR1 and IR2, total, age-specific and sex-specific annual
20 incidence rates for anorexia nervosa for the year 2015 and 95% confidence intervals were
21 calculated based on the Poisson distribution²⁰ using the Stata command *ci means [N new*
22 *anorexia nervosa cases 12m], Poisson [exposure(total population)]* for positive
23 integers/whole incidence numbers (Stata interprets any non-integer decimal point number
24 between 0 and 1 as the fraction of events and converts it to an integer number). Annual
25 incidence rates were stratified by discrete age and sex.
26
27
28
29
30

31 32 ***Public and patient involvement statement***

33
34 The CostED study included a patient and a parent representative on the study steering
35 committee who contributed to the design, conduct and management of the study, including
36 the incidence component.
37
38
39

40 41 **Results**

42 43 ***Case ascertainment***

44 Case ascertainment is outlined in Figure 1. Over the eight-month surveillance period, 6401
45 yellow cards were sent to reporting clinicians and 3211 were returned (50%). Of these, 997
46 positive cases of anorexia nervosa were reported and 2214 were nil returns. Of the positive
47 cases, 48 (5%) were excluded due to clinicians stating that they did not wish to be included in
48 the study (due to retirement, shortage of reporting capacity etc.) or due to reporting errors.
49 Questionnaires were sent to the remaining 949, and a further 352 positive cases (37%) were
50 excluded as they failed to return the questionnaires, so no data were available to assess
51 eligibility. Questionnaires were completed and returned for 597 notified cases, of which 292
52 (49%) were ineligible for reasons related to age, previous episode of anorexia nervosa, date
53 of assessment outside the study's surveillance period, referral from another secondary care
54
55
56
57
58
59
60

1
2
3 service, insufficient information to assess diagnosis or duplicate notifications, leaving 305
4 incident cases of anorexia nervosa as the sample for analysis.
5
6
7

8 ***Demographics and clinical features***

9
10 Of the 305 young people identified as having DSM5 anorexia nervosa, the majority were
11 girls (91%), from England (70%) and of white ethnicity (92%) (see Table 1). The mean age
12 was 14.6 years (± 1.66). Clinical variables suggest these young people were significantly
13 impaired. Mean BMI was 16.50 kg/m² (± 2.25), where values of 16.00 to 16.99 suggesting
14 moderate severity of anorexia nervosa. Mean percentage of median expected BMI for age and
15 sex (the deviation from expected body weight) was 83.23% ($\pm 10.99\%$), falling within the
16 range required for a diagnosis of anorexia nervosa (<85%). Mean CGAS score was 44.61
17 (± 14.08), which falls within the range for 'obvious problems' (41–50) on a scale from 1 to
18 100 (1 being the worst and 100 the best emotional and behavioural functioning). Mean total
19 HoNOSCA score was 19.40 (± 8.17) on a scale from 0 to 52, indicative of a severity similar to
20 that at inpatient admission.^{21,22}
21
22
23
24
25
26
27
28
29

30
31 The proportion of the included sample notified from each region within the British Isles is
32 reported in Table 2, alongside the population of young people in each region by age. England
33 has the largest population (78%) and notified 70% of new cases. Scotland, containing only
34 7% of the total population, notified 14% of the sample and Northern Ireland, containing only
35 3% of the population, notified 13% of the sample. By contrast, the Republic of Ireland
36 notified only 2% of cases, despite containing 8% of the population, and Wales notified no
37 eligible cases (some cases were notified but did not meet inclusion criteria), despite
38 containing 4% of the population.
39
40
41
42
43
44
45

46 ***Incidence rates***

47
48 Table 3 details observed incidence rates (IR0) and adjusted incidence rates (IR1 and IR2) by
49 age. Incidence rates for the total sample ranged from a minimum of 5.75 per 100,000 young
50 people (95% CI 5.23 to 6.30; IR0) to a maximum of 18.22 per 100,000 young people (95%
51 CI 17.29 to 19.18; IR2), with IR1, the rate hypothesised to be the most accurate, falling
52 between these two values at 13.68 per 100,000 population (95% CI 12.88 to 14.52). Focusing
53 on IR1 rates, total incidence increased steadily with age, peaking at 16 (30.37, 95% CI 26.70
54 to 34.41), with a substantial drop at the age of 17 (14.35, 95% CI 11.88 to 17.19).
55
56
57
58
59
60

1
2
3 Table 4 reports incidence rates by age and sex. Incidence among young men followed a
4 similar pattern to overall incidence rates reported in Table 3, being highest at the age of 16
5 (5.14) and half that at age 17 (2.54). The highest incidence among young women was seen a
6 year earlier than for boys, at the age of 15 (57.77), with similar rates at age 16 (56.95),
7 dropping by more than half at age 17 (26.82).
8
9
10
11
12

13 **Discussion**

14 *Principal findings*

15 This study provides new estimates of incident cases of anorexia nervosa in young people
16 aged 8 to 17 presenting to CAMHS services in the UK and Republic of Ireland. Our mid-
17 range, missing data-adjusted estimate (IR1) of the incidence of anorexia nervosa in the full
18 sample of young people aged 8 to 17 years was approximately 14 per 100,000.
19
20
21
22
23
24
25

26 *Comparison with other studies*

27 This result is lower than previous primary care-based estimates of 18–20 per 100,000
28 focusing on young people aged 10–19.^{2,5} This difference is due to the different age ranges in
29 the studies; the inclusion of children as young as 8 in the current study, who have relatively
30 low incidence, and exclusion of adolescents aged 18 to 19, whose incidence is relatively high,
31 makes the results difficult to compare. However, comparing rates for 10 to 14-year olds,
32 available in both studies, produces similar incidence rates, with rates of 12.6 per 100,000 in
33 the current study, compared to 13.1 per 100,000 in 2009.² For females, the rates are 23.3 per
34 100,000 in the current study compared to 24.0 per 100,000 in 2009 and for males, 2.4 and 2.5
35 per 100,000, respectively. However, this comparison should be treated with caution given the
36 very different settings – primary care versus secondary care.
37
38
39
40
41
42
43
44
45

46 Existing secondary care estimates of the incidence of anorexia nervosa in the UK are limited
47 to children under the age of 13, with an overall incidence of 1.09 per 100,000 reported for
48 children aged between 6 and 13 between 2005 and 2006.⁷ The methodology for this study was
49 very similar to the CostED methodology, using the CAPSS system but additionally the British
50 Paediatric Surveillance System. For comparison with the current study, the incidence rate for
51 children between 8 and 13 was approximately 1.5 per 100,000 for DSMIV anorexia nervosa or
52 1.8 per 100,000 for DSMIV anorexia nervosa plus ‘other eating disorders’ likely to contain
53 cases that would now be classified as anorexia nervosa using DSM5. This compares to a rate
54 of 5.83 per 100,000 in the current study for children of the same age. This estimate is
55
56
57
58
59
60

1
2
3 substantially higher than the 2006 estimates suggesting that incidence rates for younger
4 children have increased over time.
5
6
7

8 The results presented are also supported by international evidence. One study carried out in
9 Italy demonstrated a significant reduction in age at onset for anorexia nervosa in consecutive
10 outpatient referrals between 1985 and 2008 (n=1,666).²³ A second study exploring time trends
11 in the incidence of anorexia nervosa, which was carried out using data from the Norwegian
12 National Patient Register, found overall rates of anorexia nervosa to be stable between 2010
13 and 2016 for the sample as a whole, but increasing for young females aged between 10 and
14 14.²⁴
15
16
17
18
19
20
21

22 ***Strengths and weaknesses of the study***

23 The large, nationally representative sample of this study is a strength. The study included
24 young people with anorexia nervosa, diagnosed using DSM5 criteria, from across the UK and
25 the Republic of Ireland and thus avoided biases inherent in studying clinical samples via a
26 small number of centres in a limited number of geographical areas. The results are of
27 relevance primarily to the UK and Republic of Ireland but may be of value to other high-
28 income countries.
29
30
31
32
33
34
35

36 With only a 50% response rate from CAPSS clinicians and a third of questionnaires not
37 returned, missing data were a major constraint. There are many reasons why clinicians may
38 fail to return notification cards or questionnaires, including changes in place of employment,
39 competing priorities, or the belief that cases will be reported by a colleague.¹³ This problem
40 was addressed by adjusting the observed incidence rates using assumptions about incidence
41 among both missing case notifications and missing questionnaires.
42
43
44
45
46
47

48 The methodology is also limited to young people seen by child and adolescent psychiatrists.
49 Cases that would not be identified by this methodology include those who have not come to
50 the attention of services, for example those who choose not to seek help, those managed by
51 general practitioners in primary care, and those in the care of mental health services without
52 psychiatric input, such as nurse-led facilities. This latter concern was an issue in Northern
53 Ireland where, due to initial low numbers of notifications, investigation by the research team
54 identified a number of nurse-led facilities which were invited to contribute, and subsequently
55 reported just over half of all cases in Northern Ireland. In terms of missing primary care
56
57
58
59
60

1
2
3 cases, given UK guidelines for assessment and diagnosis of anorexia nervosa to be carried
4 out by child and adolescent psychiatrists in secondary care settings,¹⁰ it is reasonable to
5 assume that many of those cases remaining in primary care would not meet criteria for DSM5
6 anorexia nervosa. It is also possible that current inpatient cases are under-represented;
7 although notifications were sent to all child and adolescent psychiatrists, including those
8 working in inpatient settings, the main focus of the CostED study was the evaluation of
9 community-based services, and so clinicians may have mistakenly focused on notification of
10 community-based cases.
11
12
13
14
15
16
17
18

19 It must also be borne in mind that service-level (rather than population-level) incidence rates
20 are sensitive to external factors, including service availability, funding and commissioning
21 decisions, parental and school awareness, stigma, etc., all of which will impact upon observed
22 trends in incidence rates over time. The nature of community-based eating disorders services
23 for children and adolescents in England has started to change following the publication of
24 commissioning standards in June 2015,²⁵ as well as investment of £30 million to support the
25 development of these services. The CostED incidence data were collected in 2015, one year
26 before the first allocation of funding to services was made in 2016, and thus these initiatives,
27 which may result in increases in observed incidence rates in the future, are not reflected in the
28 data presented. Nevertheless, these estimates are approximately ten years more recent than
29 existing secondary care data for the UK (collected between 2005 and 2006)⁷ and cover a
30 wider age range.
31
32
33
34
35
36
37
38
39
40

41 ***Unanswered questions and future research***

42 Future research should explore the development of earlier interventions, given evidence of an
43 increase in incidence in young children suggesting that onset of anorexia nervosa may be
44 starting earlier for some young people than suggested by previous research. Research is also
45 needed to identify approaches to the assessment of incidence simultaneously in primary and
46 secondary care. Multinational studies should be considered for better assessment and
47 exploration of incidence rates in young men.
48
49
50
51
52
53
54

55 ***Conclusion***

56 These results provide new estimates of the incidence of anorexia nervosa in young people in
57 the UK and Republic of Ireland. Whilst firm conclusions relating to changes in incidence
58 rates over time for the entire sample cannot be drawn due to lack of existing secondary care
59
60

evidence, service providers and commissioners should consider evidence to suggest an increase in incidence in younger children.

Word count

4111

Acknowledgements

We would like to thank all the clinicians who were kind enough to give up their time to provide the CostED study with CAPSS notifications and to complete questionnaires. We know your time is precious and in short supply and we are truly grateful. We would also like to thank the team at the Child and Adolescent Psychiatry Surveillance System, based at the Royal College of Psychiatrist's Centre for Care Quality and Improvement, for their support with the design and running of the surveillance aspect of this study, and the study steering committee for their invaluable advice.

Contributor and guarantor information

Hristina Petkova contributed to data collection, data entry, data cleaning, data analysis, and drafting of the manuscript.

Mima Simic was a co-applicant, contributed to the design of the study, provided clinical expertise, and commented on and approved the manuscript.

Dasha Nicholls was a co-applicant, contributed to the design of the study, provided expertise on CAPSS methodology, clinical expertise, and commented on and approved the manuscript.

Tamsin Ford was a co-applicant, contributed to the design of the study, provided clinical expertise, and commented on and approved the manuscript.

Matthew Prina contributed to the data analysis and commented on and approved the manuscript.

Ruth Stuart contributed to data collection, data entry, data cleaning and data analysis, and commented on and approved the manuscript.

Nuala Livingstone contributed to data collection, data entry and data management in Northern Ireland, and commented on and approved the manuscript.

Grace Kelly contributed to data collection, data entry and data management in Northern Ireland, and commented on and approved the manuscript.

Geraldine Macdonald contributed to the design of the study, managed the Northern Ireland research staff, and commented on and approved the final report.

Ivan Eisler was a co-applicant, contributed to the design of the study, provided clinical support to the research team, and commented on and approved the manuscript.

Simon Gowers was a co-applicant, contributed to the design of the study, provided clinical expertise, and commented on and approved the manuscript.

Barbara Barrett was a co-applicant, contributed to the design of the study, the data analysis, and commented on and approved the manuscript.

Sarah Byford was principal investigator, led the study, managed the King's College London research staff, contributed to the design of the study and the data analysis, drafted the paper, and is responsible for the overall content as guarantor.

Competing interests

Tamsin Ford reports she is Chair of the Child and Adolescent Psychiatry Surveillance Service that was used to run part of the study, which is an unpaid position (other than travel expenses). Kandarp Joshi reports that he was principal investigator for the Aberdeen site for a Sunovion sponsored multisite trial on effectiveness of Lurasidone in paediatric schizophrenia. No other authors report conflicts of interest.

Transparency statement

The lead author affirms that this manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned and registered have been explained.

Role of the funding source

The study was funded by the NIHR Health Service & Delivery Research programme (11/1023/17). The study funders had no role in the study design, the collection, analysis or interpretation of data, the writing of the report, or the decision to submit the article for publication. The authors were independent from the funders and all authors had full access to all of the data in the study and can take responsibility for the integrity of the data and the accuracy of the data analysis.

Disclaimer

The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care.

Data sharing

As a result of the collection of confidential patient data without consent, and approval from the Health Research Authority (following advice from the Confidentiality Advisory Group) for data to be provided for the purposes of the specified activity only, the data cannot be made publicly available for other purposes. However, the CostED research group will consider requests for further analysis on a case by case basis, subject to appropriate ethical/HRA approvals. All data enquiries should be submitted to the corresponding author for consideration in the first instance.

For peer review only

References

- 1 Arcelus J, Mitchell AJ, Wales J, Nielsen S. Mortality rates in patients with anorexia nervosa and other eating disorders: A meta-analysis of 36 Studies. *Arch Gen Psychiatry* 2011;68:724–731.
- 2 Micali N, Hagberg KW, Petersen I, Treasure JL. The incidence of eating disorders in the UK in 2000-2009: findings from the General Practice Research Database. *BMJ Open* 2013;3:e002646.
- 3 Hoek HW. Incidence, prevalence and mortality of anorexia nervosa and other eating disorders. *Curr Opin Psychiatry* 2006;19:389–394.
- 4 Smink FRE, van Hoeken D, Hoek HW. Epidemiology of eating disorders: incidence, prevalence and mortality rates. *Current Psychiatry Reports* 2012;14:406–414.
- 5 Currin L, Schmidt U, Treasure J, Jick H. Time trends in eating disorder incidence. *Br J Psychiatry* 2005;186:132–135.
- 6 House J, Schmidt U, Craig M, et al. Comparison of specialist and nonspecialist care pathways for adolescents with anorexia nervosa and related eating disorders. *Int J Eat Disord* 2012;45:949–956.
- 7 Nicholls DE, Lynn R, Viner RM. Childhood eating disorders: British national surveillance study. *Br J Psychiatry* 2011;98:295–301.
- 8 Lask B, Bryant-Waugh R, Wright F, Campbell M, Willoughby K, Waller G. Family physician consultation patterns indicate high risk for early-onset anorexia nervosa. *Int J Eat Disord* 2005;38:269–272.
- 9 Goodman R, Ford T, Simmons H, Gatward R, Meltzer H. Using the Strengths and Difficulties Questionnaire (SDQ) to screen for child psychiatric disorders in a community sample. *Br J Psychiatry* 2000;177:534–539.
- 10 National Institute for Health and Care Excellence. Eating disorders: recognition and treatment. NICE guideline [NG69]. National Institute for Health and Care Excellence, 2017.
- 11 Byford S, Petkova H, Stuart R, et al. Alternative community-based models of care for young people with anorexia nervosa: the CostED national surveillance study. *Health Service and Delivery Research* 2019 (in press).
- 12 Lynn RM, Viner RM, Nicholls DE. Ascertainment of early onset eating disorders: a pilot for developing a national child psychiatric surveillance system. *Child Adolesc Ment Health* 2012;17:109–112.

- 1
2
3 13 Knowles RL, Friend H, Lynn R, Mitchell S, Michie C, Ihekweazu C. Surveillance of
4 rare diseases: a public health evaluation of the British Paediatric Surveillance Unit. *J*
5 *Public Health* 2012;34:279–286.
6
7
8
9 14 American Psychiatric Association. Diagnostic and Statistical Manual of Mental
10 Disorders (DSM–5), Fifth Edition. Washington DC: American Psychiatric
11 Association, 2013.
12
13 15 Le Grange D, Doyle PM, Swanson SA, Ludwig K, Glunz K, Kreipe RE. Calculation
14 of expected body weight in adolescents with eating disorders. *Pediatrics*
15 2012;129:e438–e446.
16
17
18 16 Gowers SG, Harrington RC, Whitton A, et al. Brief scale for measuring the outcomes
19 of emotional and behavioural disorders in children: Health of the Nation Outcome
20 Scales for Children and Adolescents (HoNOSCA). *Br J Psychiatry* 1999;174:413–
21 416.
22
23
24 17 Shaffer D, Gould MS, Brasic J, et al. A children's global assessment scale (CGAS).
25 *Arch Gen Psychiatry* 1983;40:1228–1231.
26
27
28 18 Office for National Statistics. Population Estimates for UK, England and Wales,
29 Scotland and Northern Ireland. Office for National Statistics, 2015.
30
31
32 19 Central Statistics Office for the Republic of Ireland. PEA11: Population estimates
33 from 1926 by Single Year of Age, Sex and Year,
34 [https://www.cso.ie/px/pxeirestat/Statire/SelectVarVal/Define.asp?maintable=PEA11](https://www.cso.ie/px/pxeirestat/Statire/SelectVarVal/Define.asp?maintable=PEA11&PLanguage=0)
35 &PLanguage=0.
36
37
38 20 Hakulinen T, Dyba T. Precision of incidence predictions based on Poisson distributed
39 observations. *Stat Med* 1994;13:1513–1523.
40
41
42 21 Gowers S, Levine W, Bailey-Rogers S, Shore A, Burhouse E. Use of a routine, self-
43 report outcome measure (HoNOSCA-SR) in two adolescent mental health services.
44 *Br J Psychiatry* 2002;180:266–269.
45
46
47 22 Gowers SG, Clark A, Roberts C, et al. Clinical effectiveness of treatments for
48 anorexia nervosa in adolescents: Randomised controlled trial. *Br J Psychiatry*
49 2007;191:427–435.
50
51
52 23 Favaro A, Caregaro L, Tenconi E, Bosello R, Santonastaso P. Time trends in age at
53 onset of anorexia nervosa and bulimia nervosa. *J Clin Psychiatry* 2009;70:1715–1721
54
55
56 24 Reas DL, Rø O. Time trends in healthcare-detected incidence of anorexia nervosa and
57 bulimia nervosa in the Norwegian National Patient Register (2010–2016). *Int J Eat*
58 *Disord* 2018;51:1144–1152.
59
60

- 1
2
3 25 NHS England. Access and Waiting Time Standard for Children and Young People
4 with an Eating Disorder: Commissioning Guide. London: National Collaborating
5 Centre for Mental Health, 2015.
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Table 1 Characteristics of incident cases

	N	Mean (SD) or %
Age	305	14.56 (1.66)
Sex		
Female	279	91.48%
Male	26	8.52%
Ethnicity		
Any White	274	91.64%
White and Asian	6	2.01%
White and Black Caribbean	2	0.67%
White and Black African	1	0.33%
Other Mixed	1	0.33%
Indian	3	1.00%
Pakistani	2	0.67%
Bangladeshi	1	0.33%
Other Asian	4	1.34%
Black Caribbean	2	0.67%
Chinese	1	0.33%
Ethnicity not known	2	0.67%
Clinical status		
BMI	304	16.50 (2.25)
% of median expected BMI	303	83.23 (10.99)
CGAS	280	44.61 (14.08)
HoNOSCA	63	19.40 (8.17)

Table 2 Cases by region of the UK and Republic of Ireland

Region	Incident cases N	Incident cases %*	Population N	Population %
England	213	69.84%	6,194,444	77.83%
Scotland	44	14.43%	561,490	7.06%
Northern Ireland	41	13.44%	231,822	2.91%
Republic of Ireland	7	2.30%	628,251	7.89%
Wales	0	0.00%	342,627	4.31%
Total	305		7,958,634	

* Does not sum to 100 due to rounding

Table 3 Annual incidence of anorexia nervosa in young people aged 8 to 17 for 2015, reported per 100,000 young people

Age	Observed rate IR0		Adjusted rate IR1		Adjusted rate IR2	
	IR	95% CI	IR	95% CI	IR	95% CI
8	0.18	0.01 to 0.76	0.43	0.10 to 1.14	0.57	0.18 to 1.35
9	0.18	0.01 to 0.77	0.44	0.11 to 1.17	0.58	0.18 to 1.38
10	0.19	0.01 to 0.80	0.45	0.11 to 1.21	0.60	0.19 to 1.43
11	1.53	0.79 to 2.67	3.65	2.43 to 5.25	4.85	3.43 to 6.65
12	4.91	3.47 to 6.76	11.69	9.39 to 14.38	15.56	12.89 to 18.63
13	8.39	6.44 to 10.73	19.95	16.89 to 23.42	26.58	23.02 to 30.54
14	11.71	9.41 to 14.39	27.85	24.25 to 31.84	37.10	32.92 to 41.66
15	12.39	10.05 to 15.10	29.47	25.80 to 33.52	39.25	35.50 to 43.88
16	12.76	10.42 to 15.47	30.37	26.70 to 34.41	40.45	36.19 to 45.07
17	6.03	4.47 to 7.96	14.35	11.88 to 17.19	19.12	16.24 to 22.35
Total	5.75	5.23 to 6.30	13.68	12.88 to 14.52	18.22	17.29 to 19.18

Table 4 Annual incidence of anorexia nervosa in young people aged 8 to 17 for 2015 by sex, reported per 100,000 young people

Age	Observed incidence IR0				Adjusted incidence IR1				Adjusted incidence IR2			
	Female	95% CI	Male	95% CI	Female	95% CI	Male	95% CI	Female	95% CI	Male	95% CI
8	0.36	0.02 to 1.55	0.00	0.00 to 0.00	0.87	0.21 to 2.34	0.00	0.00 to 0.00	1.16	0.36 to 2.76	0.00	0.00 to 0.00
9	0.00	0.00 to 0.00	0.35	0.02 to 1.52	0.00	0.00 to 0.00	0.85	0.21 to 2.28	0.00	0.00 to 0.00	1.13	0.35 to 2.69
10	0.39	0.02 to 1.65	0.00	0.00 to 0.00	0.93	0.23 to 2.48	0.00	0.00 to 0.00	1.23	0.39 to 2.93	0.00	0.00 to 0.00
11	2.35	1.07 to 4.46	0.75	0.15 to 2.18	5.59	3.47 to 8.51	1.77	0.71 to 3.63	7.44	4.96 to 10.72	2.37	1.11 to 4.42
12	8.05	5.43 to 11.50	1.92	0.80 to 3.86	19.17	14.98 to 24.16	4.56	2.69 to 7.22	25.53	20.66 to 31.21	6.09	3.89 to 9.08
13	16.36	12.48 to 21.06	0.78	0.16 to 2.28	38.93	32.81 to 45.86	1.85	0.75 to 3.79	51.83	44.72 to 59.74	2.47	1.16 to 4.62
14	22.35	17.83 to 27.67	1.53	0.56 to 3.32	53.19	46.08 to 61.10	3.64	2.00 to 6.07	70.84	62.58 to 79.88	4.84	2.91 to 7.55
15	24.28	19.59 to 29.74	1.11	0.33 to 2.71	57.77	50.41 to 65.90	2.65	1.31 to 4.78	76.93	68.39 to 86.23	3.54	1.95 to 5.91
16	23.94	19.36 to 29.28	2.16	0.99 to 4.11	56.95	49.75 to 64.90	5.14	3.20 to 7.83	75.87	67.52 to 84.97	6.85	4.57 to 9.87
17	11.27	8.22 to 15.08	1.07	0.32 to 2.60	26.82	21.98 to 32.40	2.54	1.25 to 4.58	35.71	30.09 to 42.07	3.39	1.87 to 5.67
Total	10.78	9.77 to 11.87	0.96	0.68 to 1.30	25.66	24.09 to 27.30	2.28	1.84 to 2.79	34.17	32.36 to 36.06	3.03	2.52 to 3.62

1
2
3 **Figure legends**
4

5
6 Figure 1 Flow diagram of case ascertainment
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Web extras

Case notification definition

Please report any child/young person aged 8 to 17 years and 11 months inclusive, who meets the case notification definition criteria below for the first time in the last month. One bullet point criterion from each group below should be fulfilled.

Group A

- Restriction of food, low body weight, or
- Weight less than expected for age

Group B

- Fear of gaining weight, or
- Fear of becoming fat, or
- Behaviour that interferes with weight gain, for example excessive exercising, self-induced vomiting, use of laxatives and diuretics


Group C

- Body image disturbance, or
- Persistent lack of recognition of the seriousness of the current low body weight

Exclusions

- Patients who are not underweight
- Patients with bulimia nervosa, binge eating disorder, avoidant restrictive food intake disorder or other failure to thrive presentations

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



STROBE Statement—Checklist of items that should be included in reports of *cross-sectional studies*

	Item No	Recommendation	Page No
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	5
Objectives	3	State specific objectives, including any prespecified hypotheses	5
Methods			
Study design	4	Present key elements of study design early in the paper	5-6
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	5 (setting, location), 6 (dates), 7-8 (data)
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	6 (eligibility), 8 (selection)
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	7-8 (outcomes), 8 (diagnostic criteria)
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	7-8
Bias	9	Describe any efforts to address potential sources of bias	10, 14
Study size	10	Explain how the study size was arrived at	n/a – population level
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	9-11
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	11
		(b) Describe any methods used to examine subgroups and interactions	n/a
		(c) Explain how missing data were addressed	9-11
		(d) If applicable, describe analytical methods taking account of sampling strategy	n/a
		(e) Describe any sensitivity analyses	n/a
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	11, Figure 1
		(b) Give reasons for non-participation at each stage	11, Figure 1
		(c) Consider use of a flow diagram	Figure 1

1 2 3 4 5	Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	12, 22 (Table 1)
6 7			(b) Indicate number of participants with missing data for each variable of interest	22 (Table 1)
8 9	Outcome data	15*	Report numbers of outcome events or summary measures	n/a
10 11 12 13 14 15 16	Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	12-13, 24-25 (Tables 3 & 4)
17 18			(b) Report category boundaries when continuous variables were categorized	n/a
19 20 21			(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	n/a
22 23 24	Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	n/a
25	Discussion			
26 27 28	Key results	18	Summarise key results with reference to study objectives	13
29 30 31 32	Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	14-15
33 34 35 36 37	Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	15 (interpretation), 13-14 (comparison with similar studies)
38 39 40	Generalisability	21	Discuss the generalisability (external validity) of the study results	14
41	Other information			
42 43 44 45	Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	17

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.